Codexis (CDXS) 10-Q 6 Nov 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-34705
Entity Registrant Name	Codexis, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	71-0872999
Entity Address, Address Line One	200 Penobscot Drive,
Entity Address, City or Town	Redwood City,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
City Area Code	650
Local Phone Number	421-8100
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CDXS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		59,281,805
Entity Central Index Key	0001200375
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 71,516	$ 90,498
Restricted cash, current	633	661
Financial assets:
Accounts receivable	10,711	9,063
Contract assets	975	1,027
Unbilled receivables	14,985	10,099
Total Financial assets	26,671	20,189
Less: allowances	(74)	(34)
Total Financial assets, net	26,597	20,155
Inventories	737	371
Prepaid expenses and other current assets	3,450	2,520
Total current assets	102,933	114,205
Restricted cash	1,062	1,062
Investment in Equity Securities	1,000	0
Right-of-use assets - Operating leases, net	21,996	23,837
Right-of-use assets - Finance leases, net	145	268
Property and equipment, net	7,289	6,282
Goodwill	3,241	3,241
Other non-current assets	353	178
Total assets	138,019	149,073
Current liabilities:
Accounts payable	2,499	2,621
Accrued compensation	6,277	5,003
Other accrued liabilities	7,570	6,540
Current portion of lease obligations - Operating leases	2,554	1,107
Current portion of lease obligations - Finance leases	0	60
Deferred revenue	1,596	57
Total current liabilities	20,496	15,388
Deferred revenue, net of current portion	2,460	1,987
Long-term lease obligations - Operating leases	23,001	24,951
Other long-term liabilities	1,261	1,230
Total liabilities	47,218	43,556
Commitments and Contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value per share; 100,000 shares authorized; 59,232 shares and 58,877 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	6	6
Additional paid-in capital	453,294	447,920
Accumulated deficit	(362,499)	(342,409)
Total stockholders' equity	90,801	105,517
Total liabilities and stockholders' equity	$ 138,019	$ 149,073

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (shares)	5,000,000	5,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (shares)	100,000,000	100,000,000
Common stock, shares, issued (shares)	59,232,000	58,877,000
Common stock, shares outstanding (shares)	59,232,000	58,877,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 18,385	$ 21,906	$ 48,023	$ 49,808
Costs and operating expenses:
Cost of product revenue	3,642	5,067	7,882	12,230
Research and development	12,010	8,711	33,830	25,000
Selling, general and administrative	8,797	7,869	26,307	24,180
Total costs and operating expenses	24,449	21,647	68,019	61,410
Income (loss) from operations	(6,064)	259	(19,996)	(11,602)
Interest income	39	480	362	929
Other expenses, net	(50)	(403)	(125)	(615)
Income (loss) before income taxes	(6,075)	336	(19,759)	(11,288)
Provision for (benefit from) income taxes	19	(7)	331	12
Net income (loss)	$ (6,094)	$ 343	$ (20,090)	$ (11,300)
Net income (loss) per share, basic (usd per share)	$ (0.10)	$ 0.01	$ (0.34)	$ (0.20)
Net income (loss) per share, diluted (usd per share)	$ (0.10)	$ 0.01	$ (0.34)	$ (0.20)
Weighted average common stock shares used in computing net income (loss) per share, basic (shares)	59,061	58,287	58,984	55,818
Weighted average common stock shares used in computing net income (loss) per share, diluted (shares)	59,061	61,412	58,984	55,818
Product Revenue [Member]
Revenues:
Total revenues	$ 8,401	$ 10,351	$ 18,005	$ 24,588
Research and Development Revenue [Member]
Revenues:
Total revenues	$ 9,984	$ 11,555	$ 30,018	$ 25,220

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance (shares) at Dec. 31, 2018		54,065,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)	970,256	970,000
Release of stock awards (shares)		449,000
Taxes paid related to net share settlement of equity awards (shares)		(147,000)
Issuance of common stock, net of issuance costs (shares)		3,049,000
Ending balance (shares) at Sep. 30, 2019		58,386,000
Beginning balance at Dec. 31, 2018	$ 56,306	$ 5	$ 386,775	$ (330,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock-based compensation	5,783		5,783
Exercise of stock options	4,621		4,621
Taxes paid related to net share settlement of equity awards	(2,850)		(2,850)
Issuance of common stock, net of issuance costs of $129	49,871	1	49,870
Short swing profit settlement	77		77
Net income (loss)	(11,300)			(11,300)
Ending balance at Sep. 30, 2019	102,508	$ 6	444,276	(341,774)
Beginning balance (shares) at Jun. 30, 2019		57,940,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)		441,000
Release of stock awards (shares)		8,000
Taxes paid related to net share settlement of equity awards (shares)		(3,000)
Ending balance (shares) at Sep. 30, 2019		58,386,000
Beginning balance at Jun. 30, 2019	98,684	$ 6	440,795	(342,117)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock-based compensation	1,732		1,732
Exercise of stock options	1,778		1,778
Taxes paid related to net share settlement of equity awards	(51)		(51)
Issuance costs	(55)		(55)
Short swing profit settlement	77		77
Net income (loss)	343			343
Ending balance at Sep. 30, 2019	$ 102,508	$ 6	444,276	(341,774)
Beginning balance (shares) at Dec. 31, 2019		58,877,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)	87,240	87,000
Release of stock awards (shares)		370,000
Taxes paid related to net share settlement of equity awards (shares)		(102,000)
Ending balance (shares) at Sep. 30, 2020		59,232,000
Beginning balance at Dec. 31, 2019	$ 105,517	$ 6	447,920	(342,409)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock-based compensation	6,045		6,045
Non-employee stock-based compensation	47		47
Exercise of stock options	539		539
Taxes paid related to net share settlement of equity awards	(1,257)		(1,257)
Net income (loss)	(20,090)			(20,090)
Ending balance at Sep. 30, 2020	90,801	$ 6	453,294	(362,499)
Beginning balance (shares) at Jun. 30, 2020		59,125,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)		55,000
Release of stock awards (shares)		70,000
Taxes paid related to net share settlement of equity awards (shares)		(18,000)
Ending balance (shares) at Sep. 30, 2020		59,232,000
Beginning balance at Jun. 30, 2020	94,786	$ 6	451,185	(356,405)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock-based compensation	1,941		1,941
Non-employee stock-based compensation	43		43
Exercise of stock options	342		342
Taxes paid related to net share settlement of equity awards	(217)		(217)
Net income (loss)	(6,094)			(6,094)
Ending balance at Sep. 30, 2020	$ 90,801	$ 6	$ 453,294	$ (362,499)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 0	$ 129

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities:
Net loss	$ (20,090)	$ (11,300)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,403	1,118
Amortization expense - right-of-use assets - operating and finance leases	1,964	2,231
Gain on disposal of property and equipment	0	(2)
Stock-based compensation	6,092	5,783
Allowance for credit losses	40	0
Loss on investment in equity securities	0	526
Changes in operating assets and liabilities:
Accounts receivable, net	(1,648)	(776)
Contract assets	52	(1,158)
Unbilled receivables	(4,886)	385
Inventories	(366)	192
Prepaid expenses and other current assets	(930)	(485)
Other non-current assets	(175)	74
Accounts payable	(101)	(1,294)
Accrued compensation	1,274	(577)
Other accrued liabilities	2,307	2,687
Other long-term liabilities	(1,920)	(1,291)
Deferred revenue	2,012	(5,012)
Net cash used in operating activities	(14,972)	(8,899)
Investing activities:
Purchase of property and equipment	(2,260)	(3,315)
Proceeds from disposal of property and equipment	0	2
Investment in equity securities	(1,000)	0
Proceeds from the sale of investment securities	0	62
Net cash used in investing activities	(3,260)	(3,251)
Financing activities:
Proceeds from exercises of stock options	539	4,621
Proceeds from issuance of common stock in connection with private placement	0	50,000
Costs incurred in connection with private placement	0	(129)
Payments of lease obligations - Finance leases	(60)	(180)
Recovery of short swing profit	0	77
Taxes paid related to net share settlement of equity awards	(1,257)	(2,850)
Net cash provided by (used in) financing activities	(778)	51,539
Net increase (decrease) in cash, cash equivalents and restricted cash	(19,010)	39,389
Cash, cash equivalents and restricted cash at the beginning of the period	92,221	54,485
Cash, cash equivalents and restricted cash at the end of the period	73,211	93,874
Supplemental disclosure of cash flow information
Interest paid	15	16
Income taxes paid	312	5
Purchase of property and equipment recorded in accounts payable and accrued expenses	289	536
Total cash, cash equivalents and restricted cash at the end of the period	$ 73,211	$ 93,874

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis. We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which we have been continuously improving since our inception in 2002, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers. We are a pioneer in the harnessing of computational technologies to drive biology advancements. Since 2002, we have made substantial investments in the development of our CodeEvolver ® protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver ® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development which are all coordinated to create our novel protein innovations. Our approach to developing commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design, using our CodeEvolver ® protein engineering platform technology. Engineered protein catalyst candidates - many thousands for each protein engineering project - are then rapidly screened and validated in high throughput screening under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners. The successful embodiment of our CodeEvolver ® protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver ® protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for the Company. We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the pharmaceuticals market, which remains a primary business focus. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also licensed our proprietary CodeEvolver ® protein engineering technology platform to global pharmaceutical companies so that they may in turn use this technology to engineer enzymes for their own businesses. Most recently, in May 2019, we entered into a Platform Technology Transfer and License Agreement (the “Novartis CodeEvolver ® Agreement”) with Novartis Pharma AG (“Novartis”). The Novartis CodeEvolver ® Agreement allows Novartis to use our proprietary CodeEvolver ® protein engineering platform technology in the field of human healthcare. As evidence of our strategy to extend our technology beyond pharmaceutical manufacturing, we have also used the technology to develop protein catalysts and industrial enzymes for use in a wider set of industrial markets. These target industries consist of several large market verticals, including food and food ingredients, animal feed, consumer care, flavors, fragrances and agricultural chemicals. In addition, we are using our technology to develop enzymes for customers using next generation sequencing ("NGS") and polymerase chain reaction ("PCR/qPCR") for in vitro molecular diagnostic and genomic research applications. In December 2019, we entered into a license agreement to provide Roche Sequencing Solutions, Inc. (“Roche”) with our first enzyme for this target market, the Company's EvoT4™ DNA ligase. In June 2020, we entered into a co-marketing and enzyme supply collaboration agreement with Alphazyme LLC for the production and co-marketing of enzymes for life science applications including, initially, high-fidelity DNA polymerase, T7 RNA polymerase and reverse transcriptase enzymes. We have also begun using the CodeEvolver ® protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business. In October 2017, we entered into the "Nestlé Agreement” with Nestlé Health Science to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of phenylketonuria ("PKU"). PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114. In March 2020, we entered into a Strategic Collaboration and License Agreement (“Takeda Agreement”) with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”), for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies. Below are brief descriptions of our business segments: Performance Enzymes We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, consumer care, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. Novel Biotherapeutics We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver ® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Our first lead program was for the potential treatment of hyperphenylalaninemia (“HPA”) (also referred to as PKU) in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a global development, option and license agreement with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration that it had completed its review of our investigational drug application for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. In January 2020, we and Nestlé Health Science entered into a development agreement pursuant to which we and Nestlé Health Science are collaborating to advance a lead candidate targeting a gastro-intestinal disorder discovered through our Strategic Collaboration Agreement into pre-clinical and early clinical studies. The Strategic Collaboration Agreement was extended through December 2021. Using our CodeEvolver ® protein engineering platform technology, we have also developed a pipeline of other biotherapeutic drug candidates, all of which are in preclinical development. Our most recent achievement in novel biotherapeutics came in March 2020, when we announced a strategic collaboration and license agreement with Takeda in which we will collaborate with Takeda to research and develop protein sequences for use in gene therapy products for certain disease indications. Under the terms of the Takeda Agreement, we will generate novel gene sequences encoding protein variants tailored to enhance efficacy as a result of increased activity, stability, and cellular uptake using our CodeEvolver ® protein engineering platform. Takeda will combine these improved transgenes with its gene therapy capabilities to generate novel candidates for the treatment of rare genetic disorders. We are currently collaborating on three initial programs for the treatment of Fabry disease, Pompe disease, and an unnamed blood factor deficiency. The Company is responsible for the creation of novel enzyme sequences for advancement as gene therapies into pre-clinical development. Takeda is responsible for the pre-clinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs. Under the terms of the agreement, in addition to the three initial programs, Takeda may initiate up to four additional programs for separate target indications. In March 2020, we began research and development activities under the program plans and received a $8.5 million one-time, non-refundable cash payment. We expect to continue to make additional investments in our pipeline with the aim of advancing additional product candidates targeting other therapeutic areas. For additional discussion of our business segments, see Note 13, "Segment, Geographical and Other Revenue Information." Business Update Regarding COVID-19 We are subject to risks and uncertainties as a result of the current COVID-19 pandemic. The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, communities and business operations, as well as the U.S. economy and other economies worldwide. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and may not be accurately predicted, including the duration and severity of the pandemic and the extent and severity of the impact on our customers, new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. To date, we and our collaboration partners have been able to continue to supply our enzymes to our customers worldwide. However, we are dependent on our manufacturing and logistics partners and consequently, disruptions in operations of our partners and customers may affect our ability to supply enzymes to our customers. Furthermore, our ability to provide future research and development ("R&D") services will continue to be impacted as a result of governmental orders and any disruptions in operations of our customers with whom we collaborate. We believe that these disruptions have had a negative impact on revenue for the nine months ending September 30, 2020, although we are unable to fully determine and quantify the extent to which this pandemic has affected the amount and timing of our total revenues. The extent to which the pandemic may impact our business operations and operating results will continue to remain highly dependent on future developments, which are uncertain and cannot be predicted with confidence. In the U.S., the impact of COVID-19, including governmental orders ("Orders") governing the operation of businesses during the pandemic, caused the temporary closure of our Redwood City, California facilities and has disrupted our R&D operations. R&D operations for several projects were temporarily suspended from mid-March 2020 through the end of April in accordance with these Orders. In May 2020, we initiated limited R&D operations and have gradually ramped up operations such that we are currently utilizing the majority of our normal R&D capacity. Additionally, we have resumed small scale manufacturing at our Redwood City pilot plant in May 2020. Our future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges faced by our customers. As of the date of issuance of the unaudited condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact our financial condition, liquidity, or results of operations in the future is uncertain.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2020 are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2019 Annual Report on Form 10-K and are updated below as necessary. Certain prior year amounts have been reclassified to conform to 2020 presentation. In June 2016, the Financial Accounting Standards Board (“FASB”) issued guidance requiring implementation of a new impairment model applicable to financial assets measured at amortized cost which, among other things required that accounts receivable, contract assets, unbilled receivables and related allowances be reclassified as financial assets. Except as noted above, the unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2020, results of our operations for the three and nine months ended September 30, 2020 and 2019, changes in stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The results of the nine months ended September 30, 2020 reflect the adoption of certain accounting standards including: Accounting Standard Update ("ASU") 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which added a new impairment model applicable to our financial assets measured at amortized cost, and (ii) ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which adjusts testing for goodwill impairment. See "Recently adopted accounting pronouncements" for details regarding the adoption of these standards. The unaudited interim condensed consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, the interest rate used to adjust the promised amount of consideration for the effects of significant financial assets (comprised of accounts receivable, contract assets, and unbilled receivables), inventories, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the unaudited condensed consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain and may not be accurately predicted, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies. Financial assets and Allowances We currently sell enzymes primarily to pharmaceutical and fine chemicals companies throughout the world by the extension of trade credit terms based on an assessment of each customer's financial condition. Trade credit terms are generally offered without collateral and may include an insignificant discount for prompt payment for specific customers. To manage our credit exposure, we perform ongoing evaluations of our customers' financial conditions. In addition, accounts receivable include amounts owed to us under our collaborative research and development agreements. We recognize accounts receivable at invoiced amounts and we maintain a valuation allowance as follows: Allowance for credit losses from January 1, 2020 On and subsequent to January 1, 2020, our financial results reflect an impairment model (known as the “current expected credit loss model” or “CECL”) based on estimates and forecasts of future conditions requiring recognition of a lifetime of expected credit losses at inception on our financial assets measured at amortized costs which is comprised of accounts receivable, contract assets, and unbilled receivables. We have determined that our financial assets share similar risk characteristics including: (i) customer origination in the pharmaceutical and fine chemicals industry, (ii) similar historical credit loss pattern of customers (iii) no meaningful trade receivable differences in terms, (iv) similar historical credit loss experience and (v) our belief that the composition of certain assets are comparable to our historical portfolio used to develop loss history. As a result, we measured the allowance for credit loss (“ACL”) on a collective basis. Our ACL methodology considers how long the asset has been past due, the financial condition of the customers, which includes ongoing quarterly evaluations and assessments of changes in customer credit ratings, and other market data that we believe are relevant to the collectability of the assets. Nearly all financial assets are due from customers that are highly rated by major rating agencies and have a long history of no credit loss. We derive our ACL by establishing an impairment rate attributable to assets not yet identified as impaired. We derive our ACL by initially relying on our historical financial asset loss rate which contemplates the full contractual life of the assets sharing similar risk characteristics, adjusted to reflect (i) the extent to which we have determined current conditions differ from the conditions that existed for the period over which historical loss information was evaluated and (ii) by taking into consideration the changes in certain macroeconomic historical and forecasted information. We apply the ACL to past due financial assets and record charges to the ACL as a provision to credit loss expense in the Statement of Operations. Financial assets we identify as uncollectible are also charged against the ACL. We adjust the impairment rate to reflect the extent to which we have determined current conditions differ from the conditions that existed for the period over which historical loss information was evaluated. Adjustments to historical loss information may be qualitative or quantitative in nature and reflect changes related to relevant data. In the three and nine months ended September 30, 2020, inputs to our CECL forecast incorporated forward-looking adjustments associated with the COVID-19 pandemic which we believe are appropriate to incorporate due to the uncertainty of the economic impact on cash flows from our financial assets. Allowance for credit losses before January 1, 2020 Prior to January 1, 2020, the allowances for doubtful accounts reflected our best estimates of probable losses inherent in our accounts receivable and contract assets balances. The allowance determination was based on known troubled accounts, historical experience, and other currently available evidence. Uncollectible accounts receivable were written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries were recognized when they were received. Investment in Equity Securities We own an equity investment in Molecular Assemblies, Inc. (“MAI”) which is a privately held company. Concurrently with our initial equity investment, John Nicols, our chief executive officer, joined MAI’s board of directors, and we entered into the MAI Agreement pursuant to which we will provide technical services and expertise in exchange for compensation in the form of additional shares of voting preferred stock. We and MAI envision entering into an arrangement to commercialize products developed under the MAI Agreement. To analyze the fair value measurement of our equity investment in MAI, we perform a qualitative analysis using significant unobservable inputs. Significant changes to the unobservable inputs may result in a significantly higher or lower fair value estimate. We may value our equity investment based on significant recent arms-length equity transactions with sophisticated non-strategic unrelated new investors, providing the terms of these equity transactions are substantially similar to the equity transactions terms between the company and us. The impact of the difference in transaction terms on the market value of the portfolio company may be difficult or impossible to quantify. We evaluate our investment for impairment when circumstances indicate that we may not be able to recover the carrying value. We impair our investment when we determine that there has been an “other-than-temporary” decline in MAI's estimated fair value compared to its carrying value. We calculate the estimated fair value of the investment using information from the company, which may include: • Audited and unaudited financial statements; • Projected technological developments of the company; • Projected ability of the company to service its debt obligations; • If a deemed liquidation event were to occur; • Current fundraising transactions; • Current ability of the company to raise additional financing if needed; • Changes in the economic environment which may have a material impact on the operating results of the company; • Qualitative assessment of key management; • Contractual rights, obligations or restrictions associated with the investment; and • Other factors deemed relevant by our management to assess valuation. • The valuation may be reduced if the company's potential has deteriorated significantly. If the factors that led to a reduction in valuation are overcome, the valuation may be readjusted. Goodwill Goodwill represents the excess of consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in the trading price of our stock on the Nasdaq Global Select Market. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. We manage our business as two reporting units and we test goodwill for impairment at the reporting unit level. We allocated goodwill to the two reporting units using a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting unit. Using the relative fair value allocation methodology, we have determined that approximately 76% of goodwill was to be allocated to the Performance Enzymes segment and 24% allocated to the Novel Biotherapeutics segment. As a result of the calculation, $2.4 million of the goodwill is assigned to the Performance Enzymes segment and $0.8 million is assigned to the Novel Biotherapeutics segment. We test goodwill for impairment on an annual basis on the last day of the fourth fiscal quarter and, when specific circumstances dictate, between annual tests, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. During 2020 and 2019, we did not record impairment charges related to goodwill. We test for goodwill impairment is as follows: Goodwill impairment testing from January 1, 2020 Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. We test for impairment annually on a reporting unit basis, on the last day of the fourth fiscal quarter, and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The annual impairment test is completed using either: a qualitative “Step 0” assessment based on reviewing relevant events and circumstances; or a quantitative “Step 1” assessment, which determines the fair value of the reporting unit. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge is recorded. Using the relative fair value allocation methodology for assets and liabilities used in both of our reporting units, we compare the allocated carrying amount of each reporting unit’s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. Any excess of the reporting unit’s carrying amount of goodwill over its fair value is recognized as an impairment. Goodwill impairment testing before January 1, 2020 Prior to January 1, 2020, the goodwill impairment test consisted of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of each reporting unit to its carrying value. Using the relative fair value allocation methodology for assets and liabilities used in both of our reporting units, we compared the allocated carrying amount of each reporting unit’s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required. The second step, if required, compared the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. Implied fair value was the excess of the fair value of the reporting unit over the fair value of all identified or allocated assets and liabilities. Any excess of the reporting unit’s carrying amount goodwill over the respective implied fair value was recognized as an impairment. Interim Goodwill Impairment Testing We tested goodwill for impairment in the quarter ended September 30, 2020. Since late 2019, the COVID-19 pandemic has spread worldwide. The COVID-19 pandemic has caused a decline in global and domestic macroeconomic conditions, the general deterioration of the U.S. economy and other economies worldwide, all of which may negatively impact our overall financial performance, driving a reduction in our cash flows. We believe that the impact of the COVID-19 pandemic was a triggering event that gave rise to the need to perform a goodwill impairment test. We conducted a qualitative interim impairment assessment as of September 30, 2020, which included an evaluation of our cash flow projections to reflect the current economic environment, including the uncertainty surrounding the nature, timing, and extent of the impact of the pandemic in operating our business. We also considered the results of the prior quarters’ impairment test performed which reflected a significant cushion between the fair value and the carrying value for both of our reporting units. We determined that it was more likely than not that the fair value of each of the reporting units exceeded its respective carrying amount as of September 30, 2020. Therefore, an interim quantitative impairment test of our goodwill at the reporting unit level was not required to be performed. Segment Reporting We report two business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM"), or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. We do not allocate or evaluate assets by segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to dis cover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Performance Enzymes segment consists of protein catalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets. Income Taxes Changes to Tax Law On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), P.L. 116-136,was passed into law, amending portions of certain relevant US tax laws. The CARES Act includes a number of federal income tax law changes, including, but not limited to: (i) permitting net operating loss carrybacks to offset 100% of taxable income for taxable years beginning before 2021, (ii) accelerating alternative minimum tax credit refunds, (iii) temporarily increasing the allowable business interest deduction from 30% to 50% of adjusted taxable income, and (iv) providing a technical correction for depreciation related to qualified improvement property. The CARES Act had no impact on our unaudited condensed consolidated financial statements. Accounting Pronouncements Recently adopted accounting pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the FASB's guidance on the impairment of financial instruments. The standard adds a new impairment model, known as CECL, which replaces the probable loss model. The CECL impairment model is based on estimates and forecasts of future conditions which requires recognition of a lifetime of expected credit losses at inception on financial assets measured at amortized costs. Our financial assets measured at amortized cost are comprised of accounts receivable, contract assets, and unbilled receivables. We adopted the new standard in the first quarter of 2020 using a modified retrospective approach requiring a cumulative-effect adjustment to the opening accumulated deficit as of the date of adoption. The ASU establishes a new valuation account “allowance for credit losses” replacing the “allowance for doubtful accounts” in the consolidated balance sheet, which is used to adjust the amortized cost basis of assets in presentation of the net amount expected to be collected. The adoption required certain additional disclosures but had no other impact on our unaudited condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit to its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment, and if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted the standard in the first quarter of 2020 using a prospective approach. The adoption required certain additional disclosures but had no impact on our unaudited condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The primary focus of the standard is to improve the effectiveness of the disclosure requirements for fair value measurements. The changes affect all companies that are required to include fair value measurement disclosures. The standard requires the use of the prospective method of transition for disclosures related to changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop fair value measurements categorized within Level 3 of the fair value hierarchy, and narrative description of measurement uncertainty. All other amendments in the standard are required to be adopted retrospectively. We adopted the standard in the first quarter of 2020 and the adoption had no impact on our unaudited condensed consolidated financial statements and related disclosures. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. ASU 2018-18 provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The standard also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The standard is to be applied retrospectively to the date of the initial application of Topic 606 which also requires recognition of the cumulative effect of applying the amendments as an adjustment to the opening balance of retained earnings of the later or the earliest annual period presented and the annual period inclusive of the initial application of Topic 606. We adopted the standard in the first quarter of 2020 and the adoption had no impact on our unaudited condensed consolidated financial statements and related disclosures. Recently issued accounting pronouncements not yet adopted From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our unaudited condensed consolidated financial statements upon adoption. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes . The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020, with early adoption permitted. The standard will be adopted upon the effective date for us beginning January 1, 2021. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregation of Revenue The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada and Latin America), EMEA (Europe, Middle East and Africa), and APAC (Australia, New Zealand, Southeast Asia and China). Segment information is as follows (in thousands): Three months ended September 30, 2020 Three months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product Revenue $ 8,401 $ — $ 8,401 $ 10,351 $ — $ 10,351 Research and development revenue 4,604 5,380 9,984 10,073 1,482 11,555 Total revenues $ 13,005 $ 5,380 $ 18,385 $ 20,424 $ 1,482 $ 21,906 Primary geographical markets: Americas $ 3,209 $ 2,632 $ 5,841 $ 2,706 $ — $ 2,706 EMEA 2,141 2,748 4,889 10,723 1,482 12,205 APAC 7,655 — 7,655 6,995 — 6,995 Total revenues $ 13,005 $ 5,380 $ 18,385 $ 20,424 $ 1,482 $ 21,906 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 18,005 $ — $ 18,005 $ 24,588 $ — $ 24,588 Research and development revenue 13,380 16,638 30,018 16,512 8,708 25,220 Total revenues $ 31,385 $ 16,638 $ 48,023 $ 41,100 $ 8,708 $ 49,808 Primary geographical markets: Americas $ 7,381 $ 10,591 $ 17,972 $ 9,620 $ — $ 9,620 EMEA 8,128 6,047 14,175 15,964 8,708 24,672 APAC 15,876 — 15,876 15,516 — 15,516 Total revenues $ 31,385 $ 16,638 $ 48,023 $ 41,100 $ 8,708 $ 49,808 Contract Balances The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): September 30, 2020 December 31, 2019 Contract Assets $ 975 $ 1,027 Unbilled receivables $ 14,985 $ 10,099 Contract Costs $ 130 $ — Contract Liabilities: Deferred Revenue $ 4,056 $ 2,044 We had no asset impairment charges related to contract assets in the three and nine months ended September 30, 2020 and 2019. During the nine months ended September 30, 2020, decreases in contract assets were primarily due to contract assets that were subsequently invoiced as our right to consideration for goods and services became unconditional. Increases in unbilled receivables were primarily due to the timing of billings. The increase in deferred revenue were primarily due to cash advances received in excess of revenue recognized. During the three and nine months ended September 30, 2020 and 2019, we recognized the following revenues (in thousands): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 708 $ 5,092 $ 58 $ 4,948 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 233 2,641 854 2,460 Performance obligations satisfied from new activities in the period - contract revenue 17,444 14,173 47,111 42,400 Total revenues $ 18,385 $ 21,906 $ 48,023 $ 49,808 Performance Obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2020. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands): Remainder of 2020 2021 2022 and Thereafter Total Product Revenue $ — $ 364 $ 1,623 $ 1,987 Research and development revenue 558 1,012 499 2,069 Total revenues $ 558 $ 1,376 $ 2,122 $ 4,056

Net income (loss) per Share

Net income (loss) per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net income (loss) per Share	Net income (loss) per Share Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding, less restricted stock awards ("RSAs") subject to forfeiture. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture, plus all additional common stock shares that would have been outstanding, assuming dilutive potential common stock shares had been issued for other dilutive securities. For periods of net loss, diluted and basic net loss per share are identical since potential common stock shares are excluded from the calculation, as their effect was anti-dilutive. The following table sets forth the computation of basic and diluted net income (loss) per share during the three and nine months ended September 30, 2020 and 2019 (in thousands, except per share amounts): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Numerator: Net income (loss) (6,094) 343 (20,090) (11,300) Denominator: Weighted average common stock shares used in computing net income (loss) per share, basic 59,061 58,287 58,984 55,818 Effect of dilutive shares — 3,125 — — Weighted average common stock shares used in computing net income (loss) per share, diluted 59,061 61,412 58,984 55,818 Net income (loss) per share, basic $ (0.10) $ 0.01 $ (0.34) $ (0.20) Net income (loss) per share, diluted $ (0.10) $ 0.01 $ (0.34) $ (0.20) Anti-Dilutive Securities The following shares were not considered in the computation of diluted net income (loss) per share because their effect was anti-dilutive (in thousands): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Shares issuable under the Equity Incentive Plan 5,182 1,019 5,182 5,623

Collaborative Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2020
Research and Development [Abstract]
Collaborative Arrangements	Collaborative Arrangements GSK Platform Technology Transfer, Collaboration and License Agreement In July 2014, we entered into a CodeEvolver ® protein engineering platform technology transfer collaboration and license agreement (the "GSK CodeEvolver ® Agreement") with GlaxoSmithKline ("GSK"). Pursuant to the terms of the agreement, we granted GSK a non-exclusive license to use the CodeEvolver ® protein engineering platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products. We received an upfront fee upon the execution of the agreement in July 2014 and milestone payments in each of the years from 2014 through April 2016. We completed the transfer of the CodeEvolver ® protein engineering platform technology to GSK in April 2016 and all revenues relating to the technology transfer have been recognized as of April 2016. We have the potential to receive additional cumulative contingent payments that range from $5.75 million to $38.5 million per project based on GSK’s successful application of the licensed technology. We are also eligible to receive royalties based on net sales of GSK's sales of licensed enzyme products that are currently not being recognized. In 2019, we received a $2.0 million milestone payment on the advancement of an enzyme developed by GSK using our CodeEvolver ® protein engineering platform technology. We recognized no research and development revenue for the three and nine months ended September 30, 2020 compared to $2.0 million for the three and nine months ended September 30, 2019. Merck Platform Technology Transfer and License Agreement In August 2015, we entered into a CodeEvolver ® platform technology transfer collaboration and license agreement (the "Merck CodeEvolver ® Agreement") with Merck, Sharp & Dohme ("Merck") which allows Merck to use the CodeEvolver ® protein engineering technology platform in the field of human and animal healthcare. We received an up-front license fee upon execution of the Merck CodeEvolver ® Agreement, and milestone payments in September 2015 and in September 2016, when we completed the transfer of the engineering platform technology. We have the potential to receive payments of up to a maximum of $15.0 million for each commercial active pharmaceutical ingredient ("API") that is manufactured by Merck using one or more novel enzymes developed by Merck using the CodeEvolver ® protein engineering technology platform. The API payments, which are currently not recognized in revenue, are based on the quantity of API developed and manufactured by Merck and will be recognized as usage-based royalties. In January 2019, we entered into an amendment to the Merck CodeEvolver ® Agreement to install certain CodeEvolver ® protein engineering technology upgrades into Merck’s platform license installation and maintain those upgrades for a multi-year term. The license installation was completed in 2019 and we recognized $0.1 million and $1.0 million in the three and nine months ended September 30, 2019 as a license fee revenue accordingly under the amendment. Pursuant to the agreement, Merck has options to future technology enhancements for a specified fee. As of September 30, 2020, Merck has not exercised its option for technology enhancements. We recognized research and development revenues of $1.1 million and $2.1 million for the three and nine months ended September 30, 2020, respectively, compared to $1.1 million and $4.0 million for the three and nine months ended September 30, 2019, respectively, under the Merck CodeEvolver ® Agreement. Merck Sitagliptin Catalyst Supply Agreement In February 2012, we entered into a five-year Sitagliptin Catalyst Supply Agreement (“Sitagliptin Catalyst Supply Agreement”) with Merck whereby Merck may obtain commercial scale enzyme for use in the manufacture of Januvia ® , its product based on the active ingredient sitagliptin. In December 2015, Merck exercised its option under the terms of the sitagliptin Catalyst Supply Agreement to extend the agreement for an additional five years through February 2022. Effective as of January 2016, we and Merck amended the Sitagliptin Catalyst Supply Agreement to prospectively provide for variable pricing based on the cumulative volume of sitagliptin catalyst purchased by Merck and to allow Merck to purchase a percentage of its requirements for sitagliptin catalyst from a specified third-party supplier. Merck received a distinct, functional license to manufacture a portion of its demand beginning January 1, 2018, which we recognized as research and development revenue. We have determined that the variable pricing, which provides a discount based on the cumulative volume of sitagliptin catalyst purchased by Merck, provides Merck material rights and we are recognizing product revenues using the alternative method. Under the alternative approach, we estimate the total expected consideration and allocate it proportionately with the expected sales. The Sitagliptin Catalyst Supply Agreement requires Merck to pay an annual fee for the rights to the sitagliptin technology each year for the term of the Sitagliptin Catalyst Supply Agreement. Amounts of annual license fees are based on contractually agreed prices and are on a declining scale over the term of the contract. Pursuant to the terms of the Sitagliptin Catalyst Supply Agreement, Merck may purchase supply from us for a fee based on contractually stated prices. We recognized revenue of $3.2 million and $7.0 million for the three and nine months ended September 30, 2020, respectively, compared to $3.6 million and $11.4 million in the three and nine months ended September 30, 2019, respectively, in product revenue under this agreement. Enzyme Supply Agreement In November 2016, we entered into a supply agreement whereby our customer may purchase quantities of one of our proprietary enzymes for use in its commercial manufacture of a product. Pursuant to the supply agreement, we received an upfront payment in December 2016 which was recorded as deferred revenues. Such upfront payment will be recognized over the period of the supply agreement as the customer purchases our proprietary enzyme. We additionally have determined that the volume discounts under the supply agreement provides the customer material rights and we are recognizing revenues using the alternative method. As of September 30, 2020 and December 31, 2019, we had deferred revenue balances from the supply agreement of $2.0 million. Global Development, Option and License Agreement; Strategic Collaboration Agreement; Development Agreement In October 2017, we entered into a Global Development, Option and License Agreement (the “Nestlé Agreement”) with Société des Produits Nestlé (formerly known as Nestec Ltd.) (“Nestlé Health Science”) and, solely for the purpose of the integration and the dispute resolution clauses of the Nestlé Agreement, Nestlé Health Science S.A., to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. We received an upfront cash payment of $14.0 million in 2017 upon the execution of the Nestlé Agreement, a $4.0 million milestone payment after dosing the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, and a $1.0 million milestone payment upon achievement of a milestone relating to formulation of CDX-6114. The $4.0 million milestone payment that was triggered by the initiation of the trial was received in 2018 and the $1.0 million milestone payment that was triggered by the achievement of a formulation relating to CDX-6114 was received in February 2019. The upfront payment and the variable consideration relating to the progress payment of $4.0 million and milestone payment of $1.0 million were recognized over time as the development work was performed. Revenue was recognized using a single measure of progress that depicted our performance in transferring control of the services, which was based on the ratio of level of effort incurred to date compared to the total estimated level of effort required to complete all performance obligations under the agreement. We recognized nominal research and development revenue for the three and nine months ended September 30, 2020, respectively, compared to $0.1 million and $1.8 million for the three and nine months ended September 30, 2019, respectively. In January 2019, we received notice from the FDA that it had completed its review of our investigational new drug application ("IND") for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU and paid us $3.0 million which we recognized as research and development revenue in 2019. Upon exercising its option, Nestlé Health Science assumed all responsibilities for future clinical development and commercialization of CDX-6114 was substantially completed in the fourth quarter of 2019. Other potential payments from Nestlé Health Science to us under the Nestlé Agreement include (i) development and approval milestones of up to $85.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of product. In October 2017, we also entered into a Strategic Collaboration Agreement (the “Strategic Collaboration Agreement”) with Nestlé Health Science pursuant to which we and Nestlé Health Science are collaborating to leverage the CodeEvolver ® protein engineering technology platform to develop novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. Under the Strategic Collaboration Agreement, we received an upfront payment of $1.2 million in 2017 and an incremental payment of $0.6 million in September 2018 for additional services. The Strategic Collaboration Agreement has been extended through December 2021. In January 2020, we entered into a development agreement with Nestlé Health Science pursuant to which we and Nestlé Health Science are collaborating to advance a lead candidate targeting a gastro-intestinal disorder discovered through our Strategic Collaboration Agreement into pre-clinical and early clinical studies. Under the Strategic Collaboration Agreement and development agreement, we recognized research and development fees of $2.8 million and $6.1 million for the three and nine months ended September 30, 2020, respectively, compared to $1.4 million and $3.9 million in the three and nine months ended September 30, 2019, respectively. Strategic Collaboration Agreement In April 2018, we entered into the Porton Agreement with Porton to license key elements of our biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business. Under the Porton Agreement, we are eligible to receive annual collaboration fees and research and development revenues. We received an initial collaboration fee of $0.5 million within 30 days of the effective date of the Porton Agreement, $1.5 million upon the first anniversary of the effective date of the agreeme nt, and $1.0 million upon the second anniversary of the effective date of the agreement and we are eligible to receive $1.0 million on the third anniversary of the effective date of the agreement. We completed the technica l transfer in the fourth quarter of 2018 and recognized $2.8 million in research and development revenue. We recognized revenue related to the functional license provided to Porton at a point in time when control of the license was transferred to the customer. We recognized research and development revenue related to the Porton Agreement of nil and $1.1 million in the three and nine months ended September 30, 2020, respectively, and no revenue in the three and nine months ended September 30, 2019. As of September 30, 2020 and December 31, 2019, we had deferred revenue balances related to the strategic collaboration agreement of $0.1 million and nil, respectively. Platform Technology Transfer and License Agreement In May 2019, we entered into a Platform Technology Transfer and License Agreement (the “Novartis CodeEvolver ® Agreement”) with Novartis Pharma AG (“Novartis”). The Agreement allows Novartis to use our proprietary CodeEvolver ® protein engineering platform technology in the field of human healthcare. Under the Novartis CodeEvolver ® Agreement, we are transferring our proprietary CodeEvolver ® protein engineering platform technology to Novartis over approximately 23 months, starting with the date on which we commenced the technology transfer (the “Technology Transfer Period”). As a part of this technology transfer, the Company provided to Novartis our proprietary enzymes, proprietary protein engineering protocols and methods, and proprietary software algorithms. In addition, teams of the Company and Novartis scientists participated in technology training sessions and collaborative research projects at our laboratories in Redwood City, California and at a designated Novartis laboratory in Basel, Switzerland. Upon completion of technology transfer, Novartis will have the CodeEvolver ® protein engineering platform technology installed at its designated laboratory. Pursuant to the agreement, we received an upfront payment of $5.0 million shortly after the effective date of the Novartis CodeEvolver ® Agreemen t. In the second quarter of 2020, we completed the second technology milestone transfer under the agreement and became eligible to receive a milestone payment of $4.0 million, which we subsequently received in July 2020. We are eligible to receive an additional $5.0 million upon satisfactory completion of the third technology transfer milestone. In consideration for the continued disclosure and license of improvements to our technology and materials during a multi-year period that begins on the conclusion of the Technology Transfer Period, Novartis will pay us annual payments which amount to an additional $8.0 million. The Company also has the potential to receive quantity-dependent, usage payments for each API that is manufactured by Novartis using one or more enzymes that have been developed or are in development using the CodeEvolver ® protein engineering platform technology during the period that begins on the conclusion of the Technology Transfer Period and ends on the expiration date of the last to expire licensed patent. These product-related usage payments, if any, will be paid by Novartis to us for each quarter that Novartis manufactures API using a CodeEvolver ® -developed enzyme. The usage payments will be based on the total volume of API produced using the CodeEvolver ® -developed enzyme. These usage payments can begin in the clinical stage and will extend throughout the commercial life of each API. Revenue for the combined initial license and technology transfer performance obligation, which is expected to occur over twenty-three months, is being recognized using a single measure of progress that depicts our performance in transferring control of the services, which is based on the ratio of level of effort incurred to date compared to the total estimated level of effort required to complete the performance obligation relating to the combined initial license and technology transfer. Revenue allocated to future improvements will be recognized during the Improvement Term. We recognized $0.9 million and $4.1 million in research and development revenue for the three and nine months ended September 30, 2020, respectively, compared to $3.8 million in revenue for the three and nine months ended September 30, 2019 from the Novartis CodeEvolver ® Agreement. License Agreement In December 2019, we entered a license agreement with Roche Sequencing Solutions, Inc. (“Roche”) to provide Roche with our EvoT4 DNA™ ligase high-performance molecular diagnostic enzyme. The royalty bearing license grants Roche worldwide rights to include the EvoT4 DNA™ ligase in its nucleic acid sequencing products and workflows. Under the license agreement, we received an initial collaboration fee payment within 45 days of the effective date of the agreement and we are eligible to receive an additional milestone within 60 days after the completion of technology transfer. The agreement also contemplates milestone payments to the Company upon the achievement of various development and commercialization events and royalty payments from commercial sales of the enzyme. We recognized research and development fees of $0.1 million and $0.9 million for the three and nine months ended September 30, 2020, respectively. Strategic Collaboration and License Agreement In March 2020, we entered into a Strategic Collaboration and License Agreement (the “Takeda Agreement”) with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Co. Ltd. (“Takeda”) under which we will research and develop protein sequences for use in gene therapy products for certain diseases (each, a “Field”) in accordance with each applicable program plan (each, a “Program Plan”). In March 2020, we received an up-front nonrefundable cash payment of $8.5 million and we initiated activities under three Program Plans for Fabry Disease, Pompe Disease, and an unnamed blood factor deficiency respectively (the “Initial Programs”). We are primarily responsible for the research and development of protein sequences under the Program Plans (the “Protein Sequences”) and we are eligible to earn $18.3 million of research and development fees and pre-clinical milestone payments for the Initial Programs. Takeda has the right, but not the obligation, to develop, manufacture and commercialize gene therapy products that include nucleic acid sequences that encode the Protein Sequences (“Products”) at their expense. Takeda has the right to a certain number of additional disease indications (“Reserved Target Indications”) for a limited period in which Takeda may initiate a Program Plan for one or more Reserved Target Indications (“Additional/Option Program,” with Initial Programs, the “Programs”), provided, (a) if Takeda elects to initiate an Additional/Option Program while the parties are collaborating on three other Programs at the time of such election, or (b) if Takeda elects to initiate an Additional/Option Program using the last remaining Reserved Target Indication, then Takeda must pay us an option exercise fee to initiate such Additional/Option Program. We will own all rights to the Protein Sequences and corresponding nucleic acid sequences and related intellectual property rights and Takeda will own all rights to Products and related intellectual property rights. We granted to Takeda an exclusive, worldwide, royalty-bearing, sublicensable license to use the Protein Sequences and their corresponding nucleic acid sequences to develop, manufacture and commercialize the applicable Products in the applicable Field. We also granted to Takeda a limited non-exclusive, worldwide, sublicensable license (a) to research the Protein Sequences within or outside the applicable Fields and (b) to research the Products outside of the applicable Fields, which such rights exclude Takeda's right to perform any Investigational New Drug-enabling activities. The licenses to research the Protein Sequences expire after a pre-determined period of time. The term of the Takeda Agreement begins on the Effective Date and continues on a Product-by-Product and country-by-country basis, until the expiration of Takeda’s obligation to pay royalties to the Company with respect to that Product in that country. The Takeda Agreement expires in its entirety upon the expiration of Takeda’s obligation to pay royalties to the Company with respect to the Products in all countries worldwide. Subject to the terms of the Takeda Agreement, and after the first anniversary of the Effective Date with respect to the Initial Programs or after the first anniversary of confirmation of the applicable Program Plan by the parties with respect to the Additional/Option Programs, Takeda may terminate a Program upon specified prior written notice to the Company. Subject to the terms of the Takeda Agreement, Takeda may terminate the Takeda Agreement, at will, on a Product-by-Product basis upon specified prior written notice to the Company and the Takeda Agreement in its entirety upon specified prior written notice to the Company. Subject to the terms of the Takeda Agreement, Takeda may terminate the Takeda Agreement on a Product-by-Product basis for safety reasons upon specified prior written notice to the Company. Either party may terminate the Takeda Agreement for an uncured material breach by the other party, or the other party’s insolvency or bankruptcy. We are eligible to receive certain development and commercialization milestone payments up to $100.0 million per target gene, the modulation of which would lead to the treatment of the disease indications by the applicable Product. We are also eligible to receive tiered royalties based on net sales of Products at percentages ranging from the middle-single digits to low single-digits. We recognized research and development revenue related to the Takeda Agreement of $2.6 million and $10.6 million in the three and nine months ended September 30, 2020, respectively. As of September 30, 2020, we had a deferred revenue balance of $1.9 million from Takeda. Master Collaboration and Research Agreement and Stock Purchase Agreement In June 2020, we entered into a Stock Purchase Agreement with Molecular Assemblies, Inc. ("MAI") pursuant to which we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million in connection with the transaction, our chief executive officer, John Nicols, also joined MAI’s board of directors. At the same time, we entered into a Master Collaboration and Research Agreement (the “MAI Agreement”) with MAI to engineer DNA polymerase enzymes to deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA. Under the MAI Agreement and its related statement of work (“SOW”), we will apply our CodeEvolver ® protein engineering platform technology to improve the DNA polymerase enzymes that are critical for enzymatic DNA synthesis. Based on these services, the Company is eligible to earn additional shares of MAI's Series A preferred stock. MAI will combine its advanced chemistries with our enzymes to drive the process to commercialization. Under the MAI Agreement and its associated SOW, we will engage in research and development activities to engineer DNA polymerase enzymes for the enzymatic synthesis of DNA in exchange for monthly fees in the form of shares of Series A preferred stock in MAI. We are eligible to earn such non-monetary payments over ten We recognized $0.5 million in research and development revenue in the three and nine months ended September 30, 2020 from transactions with MAI. At September 30, 2020, we had $0.5 million of financial assets due from MAI. Payment for the services was subsequently received in form of additional Series A preferred stock of MAI in October.

Cash Equivalents and Equity Sec

Cash Equivalents and Equity Securities	9 Months Ended
	Sep. 30, 2020
Cash Equivalents and Marketable Securities [Abstract]
Cash Equivalents and Equity Securities	Cash Equivalents and Equity Securities Cash equivalents at September 30, 2020 and December 31, 2019 consisted of the following (in thousands): September 30, 2020 December 31, 2019 Adjusted Cost Estimated Adjusted Cost Estimated Fair Value Money market funds (1) $ 51,488 $ 51,488 $ 71,248 $ 71,248 (1) Money market funds are classified in cash and cash equivalents on our unaudited condensed consolidated balance sheets. As of September 30, 2020, the total cash and cash equivalents balance of $71.5 million was comprised of money market funds of $51.5 million and cash of $20.0 million held with major financial institutions worldwide. As of December 31, 2019, the total cash and cash equivalents balance of $90.5 million was comprised of money market funds of $71.2 million and cash of $19.3 million held with major financial institutions worldwide. Investment in Equity Securities No single investor in MAI holds 20% or more of the voting stock. Our investment represented approximately 4% of MAI's voting stock at the time of the transaction. Concurrently with our initial equity investment, John Nicols, our chief executive officer, joined MAI’s board of directors, and we entered into the MAI Agreement pursuant to which we will provide technical services and expertise in exchange for compensation in the form of additional shares of voting preferred stock. We recorded no impairments or upward adjustments due to observable price changes in the investment in the three and nine months ended

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present the financial instruments that were measured at fair value on a recurring basis at September 30, 2020 and December 31, 2019 by level within the fair value hierarchy (in thousands): September 30, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 51,488 $ — $ — $ 51,488 December 31, 2019 Level 1 Level 2 Level 3 Total Money market funds $ 71,248 $ — $ — $ 71,248

Balance Sheets Details

Balance Sheets Details	9 Months Ended
	Sep. 30, 2020
Balance Sheets Details [Abstract]
Balance Sheets Details	Balance Sheets Details Inventories Inventories consisted of the following (in thousands): September 30, 2020 December 31, 2019 Raw materials $ 77 $ 7 Work-in-process 28 26 Finished goods 632 338 Inventories $ 737 $ 371 Property and Equipment, net Property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Laboratory equipment $ 24,837 $ 23,561 Leasehold improvements 10,774 10,804 Computer equipment and software 3,134 3,016 Office equipment and furniture 1,175 1,461 Construction in progress 602 691 Property and equipment 40,522 39,533 Less: accumulated depreciation and amortization (33,233) (33,251) Property and equipment, net $ 7,289 $ 6,282 Goodwill Goodwill had a carrying value of approximately $3.2 million as of September 30, 2020 and December 31, 2019. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrued purchases $ 3,810 $ 4,386 Accrued professional and outside service fees 3,142 1,802 Other 618 352 Total $ 7,570 $ 6,540

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans In June 2019, our board of directors (the "Board") and stockholders approved the 2019 Incentive Award Plan (the "2019 Plan"). The 2019 Plan superseded and replaced in its entirety our 2010 Equity Incentive Plan (the “2010 Plan”) which was effective in March 2010, and no further awards will be granted under the 2010 Plan; however, the terms and conditions of the 2010 Plan will continue to govern any outstanding awards thereunder. The 2010 Plan provided for the grant of incentive stock options, non-statutory stock options, restricted stock units ("RSUs"), restricted stock awards ("RSAs"), performance-contingent restricted stock units ("PSUs"), performance based options ("PBOs"), stock appreciation rights, and stock purchase rights to our employees, non-employee directors and consultants. The number of shares of our common stock available for issuance under the 2019 Plan is equal to the sum of (i) 7,897,144 shares, and (ii) any shares subject to awards granted under the 2010 Plan that were outstanding as of April 22, 2019 and thereafter terminate, expire, lapse or are forfeited; provided that no more than 14,000,000 shares may be issued upon the exercise of incentive stock options (“ISOs”). In June 2019, 8.1 million shares authorized for issuance under the 2019 Plan were registered under the Securities Act of 1933, as amended (the “Securities Act”). The 2019 Plan provides for the grant of stock options, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, other stock or cash based awards and dividend equivalents to eligible employees and consultants of the Company or any parent or subsidiary, as well as members of the Board. Stock Options The option exercise price for incentive stock options must be at least 100% of the fair value of our common stock on the date of grant and the option exercise price for non-statutory stock options is 85% of the fair value of our common stock on the date of grant, as determined by the Board. If, at the time of a grant, the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all of our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees generally have a maximum term of 10 years and vest over four years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee's termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier. Restricted Stock Units (RSUs) We also grant employees RSUs, which generally vest over either a three year period with one-third of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date or over a four year period with 25% of the shares subject to the RSU vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We may grant RSUs with different vesting terms from time to time. Performance-contingent Restricted Stock Units (PSUs) and Performance Based Options (PBOs) We also grant our executives and our non-executive employees PSUs, and we grant our executives PBOs. The PSUs and PBOs vest based upon both the successful achievement of certain corporate operating milestones in specified timelines and continued employment through the applicable vesting date. When the performance goals are deemed to be probable of achievement for these types of awards, recognition of stock-based compensation expense commences. Once the number of shares eligible to vest is determined, those shares vest in two equal installments with 50% vesting upon achievement and the remaining 50% vesting on the first anniversary of achievement, in each case, subject to the recipient’s continued service through the applicable vesting date. If the performance goals are achieved at the threshold level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to half the number of PSUs granted and one-quarter the number of shares underlying the PBOs granted. If the performance goals are achieved at the target level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to the number of PSUs granted and half of the shares underlying the PBOs granted. If the performance goals are achieved at the superior level, the number of shares eligible to vest in respect of the PSUs would be equal to two times the number of PSUs granted and equal to the number of PBOs granted. The number of shares issuable upon achievement of the performance goals at the levels between the threshold and target levels for the PSUs and PBOs or between the target level and superior levels for the PSUs would be determined using linear interpolation. Achievement below the threshold level would result in no shares being eligible to vest in respect of the PSUs and PBOs. In the first half of 2020, we awarded PSUs ("2020 PSUs") and PBOs ("2020 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including sustained revenue and performance enzyme growth, strategic advancements of biotherapeutics pipeline, safety and technology development. As of September 30, 2020, we estimated that the 2020 PSUs and 2020 PBOs performance goals would be achieved at 100% of the target level, and recognized expenses accordingly. In 2019, we awarded PSUs ("2019 PSUs") and PBOs ("2019 PBOs"), each of which commenced vesting based upon the achievement of various weighted performance goals, including sustained revenue and performance enzyme growth, strategic advancement of biotherapeutics, cash balance and strategic plan development. In the first quarter of 2020, we determined that the 2019 PSUs and 2019 PBOs performance goals had been achieved at 106% of the target level, and recognized expenses accordingly. Accordingly, 50% of the shares underlying the 2019 PSUs and PBOs vested in the first quarter of 2020 and 50% of the shares underlying the 2019 PSUs and PBOs will vest in the first quarter of 2021, in each case subject to the recipient’s continued service on each vesting date. In 2018, we awarded PSUs ("2018 PSUs") and PBOs ("2018 PBOs"), each of which commenced vesting based upon the achievement of various weighted performance goals, including core business revenue growth, cash balance, new licensing collaborations, new research and development service revenue arrangements, technology advancement and novel therapeutic enzymes advancement. In the first quarter of 2019, we determined that the 2018 PSUs and 2018 PBOs performance goals had been achieved at 118% of the target level, and recognized expenses accordingly. Accordingly, 50% of the shares underlying the 2018 PSUs and PBOs vested in the first quarter of 2019 and 50% of the shares underlying the 2018 PSUs and PBOs vested in the first quarter of 2020, in each case subject to the recipient’s continued service on each vesting date. Stock-Based Compensation Expense Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Research and development $ 385 $ 458 $ 1,279 $ 1,249 Selling, general and administrative 1,599 1,274 4,813 4,534 Total $ 1,984 $ 1,732 $ 6,092 $ 5,783 The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 (in thousands): Three Months Ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Stock options $ 619 $ 545 $ 1,735 $ 1,680 RSUs and RSAs 603 461 1,812 1,308 PSUs 295 368 922 1,075 PBOs 467 358 1,623 1,720 Total $ 1,984 $ 1,732 $ 6,092 $ 5,783 In June 2020, we granted an option to purchase 60,000 shares of common stock to a non-employee as compensation for services. The estimated fair value of the grant was valued at $0.3 million using the Black-Scholes-Merton option pricing model with the following assumptions used to estimate the fair value of non-employee stock options: (i) volatility rate at 51.9%, (ii) risk-free interest rate of 0.4% and (iii) no expected dividend yield. The option vests over 2 years from the date of grant with 50% vesting after one year and the remaining 50% vesting monthly in the second year. In August 2020, we granted an option to purchase 16,000 shares of common stock to a non-employee as compensation for services. The estimated fair value of the grant was valued at $0.1 million using the Black-Scholes-Merton option pricing model with the following assumptions used to estimate the fair value of non-employee stock options: (i) volatility rate at 50.5%, (ii) risk-free interest rate of 0.3% and (iii) no expected dividend yield. The option vests over 1 year with 100% on the first anniversary of the grant date. We recognized stock-based compensation expense related to the non-employees of $43 thousand and $47 thousand for the three and nine months ended September 30, 2020, respectively. As of September 30, 2020, unrecognized stock-based compensation expense, net of expected forfeitures, was $4.2 million related to unvested employee stock options, $0.3 million related to unvested non-employee stock options, $2.3 million related to unvested RSUs and RSAs, $0.8 million related to unvested PSUs, and $1.3 million related to unvested PBOs based on current estimates of the level of achievement. Stock-based compensation expense for these awards will be recognized through the year of 2024.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Capital Stock	Capital Stock Exercise of Options For the nine months ended September 30, 2020 and September 30, 2019, we issued 87,240 and 970,256 shares, respectively, upon option exercises at a weighted-average exercise price of $6.17 and $4.76 per share, respectively, with net cash proceeds of $0.5 million and $4.6 million, respectively. Private Offering In June 2019, we entered into a Securities Purchase Agreement with an affiliate of Casdin pursuant to which we issued and sold to Casdin 3,048,780 shares of our common stock at a purchase price of $16.40 per share. After deducting legal fees of $74 thousand from the Private Offering, our net proceeds were $49.9 million. The Private Offering was exempt from registration pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) the Securities Act, and Regulation D under the Securities Act.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases Our headquarters are located in Redwood City, California, where we occupy approximately 77,300 square feet of office and laboratory space in four buildings within the same business park of Metropolitan Life Insurance Company ("MetLife"). Our lease (“Lease”) with MetLife includes approximately 28,200 square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the “Penobscot Space”), approximately 37,900 square feet of space located at 400 Penobscot Drive, Redwood City, California (the “Building 2 Space”), and approximately 11,200 square feet of space located at 501 Chesapeake Drive, Redwood City, California (the “501 Chesapeake Space”). Until January 31, 2020, we also leased approximately 29,900 square feet of space located at 101 Saginaw Drive, Redwood City, California (the “Saginaw Space”). During the period January 1, 2020 through January 31, 2020, we subleased approximately 26,500 square feet of the Saginaw Space to Minerva Surgical, Inc. The lease and sublease for the Saginaw Space both expired at the end of January 2020. During the period from February 1, 2020 through April 30, 2020, we subleased approximately 3,400 square feet of the Saginaw Space from Minerva Surgical, Inc. The sublease expired at the end of April 2020. We entered into the initial lease with MetLife for a portion of this space in 2004 and the lease has been amended multiple times since then to adjust space and terms of the lease ("Lease"). In February 2019, we entered into an Eighth Amendment to the Lease ( the “Eighth Amendment”) with MetLife with respect to the Penobscot Space, the Building 2 Space and the 501 Chesapeake Space to extend the term of the Lease for additional periods. Pursuant to the Eighth Amendment, the term of the lease of the Penobscot Space and the Building 2 Space has been extended through May 2027. The lease term for the 501 Chesapeake Space has been extended to May 2029. We have two consecutive options to extend the term of the lease for the Penobscot Space, the Building 2 Space and the 501 Chesapeake Space for an additional period of five years per option. We are required to restore certain areas of the Redwood City facilities that we are renting to their original form. We are expensing the asset retirement obligation over the terms of the respective leases. We review the estimated obligation each reporting period and make adjustments if our estimates change. We recorded asset retirement obligations of $0.2 million as of September 30, 2020 and December 31, 2019, which are included in other liabilities on the unaudited condensed consolidated balance sheets. Accretion expense related to our asset retirement obligations was nominal. Pursuant to the terms of the Lease, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letter of credit is collateralized by deposit balances held by the bank in the amount of $1.1 million as of September 30, 2020 and December 31, 2019, and are recorded as non-current restricted cash on the unaudited condensed consolidated balance sheets. Finance Leases In December 2016, we entered into a three-year financing lease agreement with a third party supplier for the purchase of laboratory equipment that was partially financed through a finance lease of approximately $0.4 million. The lease became effective upon delivery of the equipment in February 2017, and term of the three-year lease was from February 2017 and expired in February 2020. This financing agreement was accounted for as a finance lease due to bargain purchase options at the end of the lease. In April 2017, we entered into a three-year financing lease agreement with a third-party supplier for the purchase of information technology equipment for approximately $0.3 million. The effective term of the three-year lease was from May 2017 and expired in April 2020. Lease Costs and other information Lease related costs were as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Finance lease costs: Amortization of right-of-use assets $ 27 $ 54 $ 126 $ 163 Interest on lease obligations — 2 1 8 Finance lease costs 27 56 127 171 Operating lease cost 1,033 1,139 3,133 3,417 Short-term lease cost (1) — — 47 — Sublease income — (262) (55) (727) Total lease cost $ 1,060 $ 933 $ 3,252 $ 2,861 (1) Short-term lease costs on leases with terms of over one month and less than one year. Other information related to non-cancellable finance leases and operating leases as of September 30, 2020 was as follows: Operating Leases Weighted-average remaining lease term (in years) 6.9 years Weighted-average discount rate 6.6 % Cash paid for amounts included in the measurement of lease obligations was as follows (in thousands): Nine months ended September 30, 2020 2019 Operating cash flows from operating leases $ 1,795 $ 2,456 Operating cash flows from finance leases $ — $ 9 Financing cash flows from finance leases $ 60 $ 180 As of September 30, 2020, our maturity analysis of annual undiscounted cash flows of the non-cancellable finance and operating leases are as follows (in thousands): Years ending December 31, Operating Leases 2020 (remaining 3 months) $ 1,022 2021 4,197 2022 4,285 2023 4,589 2024 4,726 2025 and thereafter 13,494 Total minimum lease payments 32,313 Less: imputed interest (6,758) Lease Obligations $ 25,555 Other Commitments We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work. The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Other Commitment Agreement Type Agreement Date Future Minimum Payment Manufacture and supply agreement with expected future payment date of December 2022 April 2016 $ 532 Development and manufacturing services agreements September 2019 3,806 Strategic Collaboration and License Agreement March 2020 520 Total other commitments $ 4,858 Credit Facility In June 30, 2017, we entered into a credit facility (the “Credit Facility”) consisting of term loans (“Term Debt”) up to $10.0 million, and advances (“Advances”) under a revolving line of credit ("Revolving Line of Credit") up to $5.0 million with an accounts receivable borrowing base of 80% of eligible accounts receivable. At September 30, 2020 and December 31, 2019, we have not drawn from the Credit Facility. We may draw on the Term Debt and the Revolving Line of Credit at any time prior to October 1, 2021 and October 1, 2024, respectively. On October 1, 2024 loans drawn under the Term Debt mature and the Revolving Line of Credit terminate. Loans made under the Term Debt bear interest through maturity equal to the greater of (i) 3.75% and (ii) the sum of (A) Index Rate (prime rate published in the Money Rates section of the Western Edition of The Wall Street Journal plus (B) 0.50%. Advances made under the Revolving Line of Credit bear interest at a variable annual rate equal to the equal to the greater of (i) 4.25% and (ii) the sum of (A) the prime rate plus (B) 1.00%. Our obligations under the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. The Credit Facility includes a number of customary covenants and restrictive financial covenants including meeting minimum product revenue levels and maintaining certain minimum cash levels with the lender. The Credit Facility's financial covenants restrict the ability of the Company to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets, or sell certain assets held at foreign subsidiaries. A failure to comply with these covenants could permit the lender to exercise remedies against us and the collateral securing the Credit Facility, including foreclosure of our properties securing the Credit Facilities and our cash. At September 30, 2020, we were in compliance with the covenants for the Credit Facility. The Credit Facility allows for interest-only payments on the Term Debt through November 1, 2022. Monthly payments of principal and interest on the Term Debt are required following the applicable amortization date. We may elect to prepay in full the Term Debt and Advances under the Revolving Line of Credit at any time. Legal Proceedings We are not currently a party to any material pending litigation or other material legal proceedings. Indemnifications We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented. Impact of COVID-19 We are subject to risks and uncertainties as a result of the current COVID-19 pandemic. The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, communities and business operations, as well as the U.S. economy and other economies worldwide. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and may not be accurately predicted, including the duration and severity of the pandemic and the extent and severity of the impact on our customers, new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. To date, we and our collaboration partners have been able to continue to supply our enzymes to our customers worldwide. However, we are dependent on our manufacturing and logistics partners and consequently, disruptions in operations of our partners and customers may affect our ability to supply enzymes to our customers. Furthermore, our ability to provide future research and development ("R&D") services will continue to be impacted as a result of governmental orders and any disruptions in operations of our customers with whom we collaborate. We believe that these disruptions have had a negative impact on revenue for the nine months ending September 30, 2020, although we are unable to fully determine and quantify the extent to which this pandemic has affected the amount and timing of our total revenues. The extent to which the pandemic may impact our business operations and operating results will continue to remain highly dependent on future developments, which are uncertain and cannot be predicted with confidence. In the U.S., the impact of COVID-19, including governmental orders ("Orders") governing the operation of businesses during the pandemic, caused the temporary closure of our Redwood City, California facilities and has disrupted our R&D operations. R&D operations for several projects were temporarily suspended from mid-March 2020 through the end of April in accordance with these Orders. In May 2020, we initiated limited R&D operations and have gradually ramped up operations such that we are currently utilizing the majority of our normal R&D capacity. Additionally, we have resumed small scale manufacturing at our Redwood City pilot plant in May 2020. Our future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges faced by our customers. As of the date of issuance of these condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact our financial condition, liquidity, or results of operations in the future is uncertain.

Related Party

Related Party	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party	Related Party Molecular Assemblies, Inc. In June 2020, we entered into a Stock Purchase Agreement with Molecular Assemblies, Inc (“MAI”) pursuant to which we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million. In connection with the transaction, our chief executive officer, John Nicols, also joined MAI’s board of directors. At the same time, we entered into a Master Collaboration and Research Agreement (the “MAI Agreement”) with MAI to engineer DNA polymerase enzymes to deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA. Under the MAI Agreement and its related statement of work (“SOW”), we will apply our CodeEvolver ® protein engineering platform technology to improve the DNA polymerase enzymes that are critical for enzymatic DNA synthesis. Based on these services, we are eligible to earn additional Series A preferred stock of MAI contingent on the achievement of certain results and milestones. MAI will combine its advanced chemistries with our enzymes to drive the process to commercialization. Under the MAI Agreement and its associated SOW, we will engage in research and development activities to engineer DNA polymerase enzymes for the enzymatic synthesis of DNA and will receive monthly fees in the form of shares of Series A preferred stock in MAI. Such non-monetary payments will be earned over ten We recognized $0.5 million in research and development revenue in the three and nine months ended September 30, 2020 from transactions with MAI. At September 30, 2020, we had $0.5 million of financial assets due from MAI. Payment for the services was subsequently received in the form of additional Series A preferred stock of MAI in October. AstraZeneca PLC Pam P. Cheng, who served as a member of our board of directors until June 2020, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sold biocatalyst products to AstraZeneca PLC and its controlled purchasing agents and contract manufacturers. We recognized $0.1 million of revenue in 2020 through the date of Ms. Cheng’s departure from our board of directors. We recognized $0.2 million and $0.6 million of revenue from transactions with AstraZeneca in the three and nine months ended September 30, 2019, respectively. At September 30, 2020 and December 31, 2019, we had no receivables from AstraZeneca.

Segment, Geographical and Other

Segment, Geographical and Other Revenue Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment, Geographical and Other Revenue Information	Segment, Geographical and Other Revenue Information Segment Information We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the CODM, or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "Corporate costs." All items not included in income (loss) from operations are excluded from the business segments. We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment. Performance Enzymes We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. Novel Biotherapeutics We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver ® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. We have also developed a pipeline of other biotherapeutic drug candidates, which are in preclinical development, and in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas. In March 2020 we entered into the Takeda Agreement with Takeda under which we will research and develop protein sequences for use in gene therapy products for certain diseases. Factors considered in determining the two reportable segments of the Company include the nature of business activities, the management structure directly accountable to our CODM for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors. Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation. Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources. The following tables provide financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands): Three months ended September 30, 2020 Three months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 8,401 $ — $ 8,401 $ 10,351 $ — $ 10,351 Research and development revenue 4,604 5,380 9,984 10,073 1,482 11,555 Total revenues 13,005 5,380 18,385 20,424 1,482 21,906 Costs and operating expenses: Cost of product revenue 3,642 — 3,642 5,067 — 5,067 Research and development (1) 5,184 6,433 11,617 5,313 3,080 8,393 Selling, general and administrative (1) 2,675 515 3,190 2,037 690 2,727 Total segment costs and operating expenses 11,501 6,948 18,449 12,417 3,770 16,187 Income (loss) from operations $ 1,504 $ (1,568) (64) $ 8,007 $ (2,288) 5,719 Corporate costs (2) (5,483) (4,912) Depreciation and amortization (528) (471) Income (loss) before income taxes $ (6,075) $ 336 (1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses. Nine months ended September 30, 2020 Nine months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 18,005 $ — $ 18,005 $ 24,588 $ — $ 24,588 Research and development revenue 13,380 16,638 30,018 16,512 8,708 25,220 Total revenues 31,385 16,638 48,023 41,100 8,708 49,808 Costs and operating expenses: Cost of product revenue 7,882 — 7,882 12,230 — 12,230 Research and development (1) 15,877 16,848 32,725 14,889 9,252 24,141 Selling, general and administrative (1) 7,395 1,728 9,123 6,499 1,768 8,267 Total segment costs and operating expenses 31,154 18,576 49,730 33,618 11,020 44,638 Income (loss) from operations $ 231 $ (1,938) (1,707) $ 7,482 $ (2,312) 5,170 Corporate costs (2) (16,526) (15,185) Depreciation and amortization (1,526) (1,273) Loss before income taxes $ (19,759) $ (11,288) (1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses. The following tables provides stock-based compensation expense included in income (loss) from operations (in thousands): Three months ended September 30, 2020 2019 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 839 $ 132 $ 1,013 $ 1,984 $ 736 $ 225 $ 771 $ 1,732 Nine months ended September 30, 2020 2019 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 2,335 $ 625 $ 3,132 $ 6,092 $ 1,973 $ 563 $ 3,247 $ 5,783 Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Customer A 23% 21% 21% 31% Customer B 15% * 13% 17% Customer C * 29% 11% 15% Customer D 14% * 22% * Customer E 13% * * * Customers that each accounted for 10% or more of accounts receivable had balances as of the periods presented as follows: Percentage of Accounts Receivables as of September 30, 2020 December 31, 2019 Customer A 36% 38% Customer B 28% 10% Customer D 14% * * Percentage was less than 10% Geographical Information Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Revenues Americas $ 5,841 $ 2,706 $ 17,972 $ 9,620 EMEA 4,889 12,205 14,175 24,672 APAC 7,655 6,995 15,876 15,516 Total revenues $ 18,385 $ 21,906 $ 48,023 $ 49,808 Identifiable long-lived assets by location was as follows (in thousands): Long-lived assets September 30, 2020 December 31, 2019 United States $ 7,289 $ 6,282 Identifiable goodwill was as follows (in thousands): As of September 30, 2020 and December 31, 2019 Performance Enzymes Novel Biotherapeutics Total Goodwill $ 2,463 $ 778 $ 3,241

Allowance for Credit Losses

Allowance for Credit Losses	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Allowance for Credit Losses	Allowance for Credit Losses An analysis of the allowance for credit losses is as follows (in thousands): Three and nine Beginning Balance January 1, 2020 $ 34 Current period provision 40 Write-offs charged against the allowance — Recoveries of amounts previously written off — Ending Balance September 30, 2020 $ 74 The following tables below summarizes accounts receivable by aging category (in thousands): September 30, 2020 31-60 Days 61-90 Days 91 days and over Total over 31 days Current Total balance Accounts receivable $ 160 $ — $ — $ 160 $ 10,551 $ 10,711 December 31, 2019 31-60 Days 61-90 Days 91 days and over Total over 31 days Current Total balance Accounts receivable $ 185 $ 7 $ 65 $ 257 $ 8,806 $ 9,063

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2020 are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2019 Annual Report on Form 10-K and are updated below as necessary. Certain prior year amounts have been reclassified to conform to 2020 presentation. In June 2016, the Financial Accounting Standards Board (“FASB”) issued guidance requiring implementation of a new impairment model applicable to financial assets measured at amortized cost which, among other things required that accounts receivable, contract assets, unbilled receivables and related allowances be reclassified as financial assets. Except as noted above, the unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2020, results of our operations for the three and nine months ended September 30, 2020 and 2019, changes in stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The results of the nine months ended September 30, 2020 reflect the adoption of certain accounting standards including: Accounting Standard Update ("ASU") 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which added a new impairment model applicable to our financial assets measured at amortized cost, and (ii) ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which adjusts testing for goodwill impairment. See "Recently adopted accounting pronouncements" for details regarding the adoption of these standards.
Use of Estimates	Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, the interest rate used to adjust the promised amount of consideration for the effects of significant financial assets (comprised of accounts receivable, contract assets, and unbilled receivables), inventories, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the unaudited condensed consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain and may not be accurately predicted, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies.
Financing assets and Allowances	Financial assets and Allowances We currently sell enzymes primarily to pharmaceutical and fine chemicals companies throughout the world by the extension of trade credit terms based on an assessment of each customer's financial condition. Trade credit terms are generally offered without collateral and may include an insignificant discount for prompt payment for specific customers. To manage our credit exposure, we perform ongoing evaluations of our customers' financial conditions. In addition, accounts receivable include amounts owed to us under our collaborative research and development agreements. We recognize accounts receivable at invoiced amounts and we maintain a valuation allowance as follows: Allowance for credit losses from January 1, 2020 On and subsequent to January 1, 2020, our financial results reflect an impairment model (known as the “current expected credit loss model” or “CECL”) based on estimates and forecasts of future conditions requiring recognition of a lifetime of expected credit losses at inception on our financial assets measured at amortized costs which is comprised of accounts receivable, contract assets, and unbilled receivables. We have determined that our financial assets share similar risk characteristics including: (i) customer origination in the pharmaceutical and fine chemicals industry, (ii) similar historical credit loss pattern of customers (iii) no meaningful trade receivable differences in terms, (iv) similar historical credit loss experience and (v) our belief that the composition of certain assets are comparable to our historical portfolio used to develop loss history. As a result, we measured the allowance for credit loss (“ACL”) on a collective basis. Our ACL methodology considers how long the asset has been past due, the financial condition of the customers, which includes ongoing quarterly evaluations and assessments of changes in customer credit ratings, and other market data that we believe are relevant to the collectability of the assets. Nearly all financial assets are due from customers that are highly rated by major rating agencies and have a long history of no credit loss. We derive our ACL by establishing an impairment rate attributable to assets not yet identified as impaired. We derive our ACL by initially relying on our historical financial asset loss rate which contemplates the full contractual life of the assets sharing similar risk characteristics, adjusted to reflect (i) the extent to which we have determined current conditions differ from the conditions that existed for the period over which historical loss information was evaluated and (ii) by taking into consideration the changes in certain macroeconomic historical and forecasted information. We apply the ACL to past due financial assets and record charges to the ACL as a provision to credit loss expense in the Statement of Operations. Financial assets we identify as uncollectible are also charged against the ACL. We adjust the impairment rate to reflect the extent to which we have determined current conditions differ from the conditions that existed for the period over which historical loss information was evaluated. Adjustments to historical loss information may be qualitative or quantitative in nature and reflect changes related to relevant data. In the three and nine months ended September 30, 2020, inputs to our CECL forecast incorporated forward-looking adjustments associated with the COVID-19 pandemic which we believe are appropriate to incorporate due to the uncertainty of the economic impact on cash flows from our financial assets. Allowance for credit losses before January 1, 2020 Prior to January 1, 2020, the allowances for doubtful accounts reflected our best estimates of probable losses inherent in our accounts receivable and contract assets balances. The allowance determination was based on known troubled accounts, historical experience, and other currently available evidence. Uncollectible accounts receivable were written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries were recognized when they were received.
Investment in Equity Securities	Investment in Equity Securities We own an equity investment in Molecular Assemblies, Inc. (“MAI”) which is a privately held company. Concurrently with our initial equity investment, John Nicols, our chief executive officer, joined MAI’s board of directors, and we entered into the MAI Agreement pursuant to which we will provide technical services and expertise in exchange for compensation in the form of additional shares of voting preferred stock. We and MAI envision entering into an arrangement to commercialize products developed under the MAI Agreement. To analyze the fair value measurement of our equity investment in MAI, we perform a qualitative analysis using significant unobservable inputs. Significant changes to the unobservable inputs may result in a significantly higher or lower fair value estimate. We may value our equity investment based on significant recent arms-length equity transactions with sophisticated non-strategic unrelated new investors, providing the terms of these equity transactions are substantially similar to the equity transactions terms between the company and us. The impact of the difference in transaction terms on the market value of the portfolio company may be difficult or impossible to quantify. We evaluate our investment for impairment when circumstances indicate that we may not be able to recover the carrying value. We impair our investment when we determine that there has been an “other-than-temporary” decline in MAI's estimated fair value compared to its carrying value. We calculate the estimated fair value of the investment using information from the company, which may include: • Audited and unaudited financial statements; • Projected technological developments of the company; • Projected ability of the company to service its debt obligations; • If a deemed liquidation event were to occur; • Current fundraising transactions; • Current ability of the company to raise additional financing if needed; • Changes in the economic environment which may have a material impact on the operating results of the company; • Qualitative assessment of key management; • Contractual rights, obligations or restrictions associated with the investment; and • Other factors deemed relevant by our management to assess valuation. • The valuation may be reduced if the company's potential has deteriorated significantly. If the factors that led to a reduction in valuation are overcome, the valuation may be readjusted.
Goodwill	Goodwill Goodwill represents the excess of consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in the trading price of our stock on the Nasdaq Global Select Market. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. We manage our business as two reporting units and we test goodwill for impairment at the reporting unit level. We allocated goodwill to the two reporting units using a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting unit. Using the relative fair value allocation methodology, we have determined that approximately 76% of goodwill was to be allocated to the Performance Enzymes segment and 24% allocated to the Novel Biotherapeutics segment. As a result of the calculation, $2.4 million of the goodwill is assigned to the Performance Enzymes segment and $0.8 million is assigned to the Novel Biotherapeutics segment. We test goodwill for impairment on an annual basis on the last day of the fourth fiscal quarter and, when specific circumstances dictate, between annual tests, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. During 2020 and 2019, we did not record impairment charges related to goodwill. We test for goodwill impairment is as follows: Goodwill impairment testing from January 1, 2020 Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. We test for impairment annually on a reporting unit basis, on the last day of the fourth fiscal quarter, and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The annual impairment test is completed using either: a qualitative “Step 0” assessment based on reviewing relevant events and circumstances; or a quantitative “Step 1” assessment, which determines the fair value of the reporting unit. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge is recorded. Using the relative fair value allocation methodology for assets and liabilities used in both of our reporting units, we compare the allocated carrying amount of each reporting unit’s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. Any excess of the reporting unit’s carrying amount of goodwill over its fair value is recognized as an impairment. Goodwill impairment testing before January 1, 2020 Prior to January 1, 2020, the goodwill impairment test consisted of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of each reporting unit to its carrying value. Using the relative fair value allocation methodology for assets and liabilities used in both of our reporting units, we compared the allocated carrying amount of each reporting unit’s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required. The second step, if required, compared the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. Implied fair value was the excess of the fair value of the reporting unit over the fair value of all identified or allocated assets and liabilities. Any excess of the reporting unit’s carrying amount goodwill over the respective implied fair value was recognized as an impairment. Interim Goodwill Impairment Testing We tested goodwill for impairment in the quarter ended September 30, 2020. Since late 2019, the COVID-19 pandemic has spread worldwide. The COVID-19 pandemic has caused a decline in global and domestic macroeconomic conditions, the general deterioration of the U.S. economy and other economies worldwide, all of which may negatively impact our overall financial performance, driving a reduction in our cash flows. We believe that the impact of the COVID-19 pandemic was a triggering event that gave rise to the need to perform a goodwill impairment test. We conducted a qualitative interim impairment assessment as of September 30, 2020, which included an evaluation of our cash flow projections to reflect the current economic environment, including the uncertainty surrounding the nature, timing, and extent of the impact of the pandemic in operating our business. We also considered the results of the prior quarters’ impairment test performed which reflected a significant cushion between the fair value and the carrying value for both of our reporting units. We determined that it was more likely than not that the fair value of each of the reporting units exceeded its respective carrying amount as of September 30, 2020. Therefore, an interim quantitative impairment test of our goodwill at the reporting unit level was not required to be performed.
Segment Reporting	Segment Reporting We report two business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM"), or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. We do not allocate or evaluate assets by segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to dis cover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Segment Information We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the CODM, or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company.
Income Taxes	Income Taxes Changes to Tax Law On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), P.L. 116-136,was passed into law, amending portions of certain relevant US tax laws. The CARES Act includes a number of federal income tax law changes, including, but not limited to: (i) permitting net operating loss carrybacks to offset 100% of taxable income for taxable years beginning before 2021, (ii) accelerating alternative minimum tax credit refunds, (iii) temporarily increasing the allowable business interest deduction from 30% to 50% of adjusted taxable income, and (iv) providing a technical correction for depreciation related to qualified improvement property. The CARES Act had no impact on our unaudited condensed consolidated financial statements.
Accounting Pronouncements	Accounting Pronouncements Recently adopted accounting pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the FASB's guidance on the impairment of financial instruments. The standard adds a new impairment model, known as CECL, which replaces the probable loss model. The CECL impairment model is based on estimates and forecasts of future conditions which requires recognition of a lifetime of expected credit losses at inception on financial assets measured at amortized costs. Our financial assets measured at amortized cost are comprised of accounts receivable, contract assets, and unbilled receivables. We adopted the new standard in the first quarter of 2020 using a modified retrospective approach requiring a cumulative-effect adjustment to the opening accumulated deficit as of the date of adoption. The ASU establishes a new valuation account “allowance for credit losses” replacing the “allowance for doubtful accounts” in the consolidated balance sheet, which is used to adjust the amortized cost basis of assets in presentation of the net amount expected to be collected. The adoption required certain additional disclosures but had no other impact on our unaudited condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit to its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment, and if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted the standard in the first quarter of 2020 using a prospective approach. The adoption required certain additional disclosures but had no impact on our unaudited condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The primary focus of the standard is to improve the effectiveness of the disclosure requirements for fair value measurements. The changes affect all companies that are required to include fair value measurement disclosures. The standard requires the use of the prospective method of transition for disclosures related to changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop fair value measurements categorized within Level 3 of the fair value hierarchy, and narrative description of measurement uncertainty. All other amendments in the standard are required to be adopted retrospectively. We adopted the standard in the first quarter of 2020 and the adoption had no impact on our unaudited condensed consolidated financial statements and related disclosures. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. ASU 2018-18 provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The standard also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The standard is to be applied retrospectively to the date of the initial application of Topic 606 which also requires recognition of the cumulative effect of applying the amendments as an adjustment to the opening balance of retained earnings of the later or the earliest annual period presented and the annual period inclusive of the initial application of Topic 606. We adopted the standard in the first quarter of 2020 and the adoption had no impact on our unaudited condensed consolidated financial statements and related disclosures. Recently issued accounting pronouncements not yet adopted From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our unaudited condensed consolidated financial statements upon adoption. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes . The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020, with early adoption permitted. The standard will be adopted upon the effective date for us beginning January 1, 2021. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada and Latin America), EMEA (Europe, Middle East and Africa), and APAC (Australia, New Zealand, Southeast Asia and China). Segment information is as follows (in thousands): Three months ended September 30, 2020 Three months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product Revenue $ 8,401 $ — $ 8,401 $ 10,351 $ — $ 10,351 Research and development revenue 4,604 5,380 9,984 10,073 1,482 11,555 Total revenues $ 13,005 $ 5,380 $ 18,385 $ 20,424 $ 1,482 $ 21,906 Primary geographical markets: Americas $ 3,209 $ 2,632 $ 5,841 $ 2,706 $ — $ 2,706 EMEA 2,141 2,748 4,889 10,723 1,482 12,205 APAC 7,655 — 7,655 6,995 — 6,995 Total revenues $ 13,005 $ 5,380 $ 18,385 $ 20,424 $ 1,482 $ 21,906 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 18,005 $ — $ 18,005 $ 24,588 $ — $ 24,588 Research and development revenue 13,380 16,638 30,018 16,512 8,708 25,220 Total revenues $ 31,385 $ 16,638 $ 48,023 $ 41,100 $ 8,708 $ 49,808 Primary geographical markets: Americas $ 7,381 $ 10,591 $ 17,972 $ 9,620 $ — $ 9,620 EMEA 8,128 6,047 14,175 15,964 8,708 24,672 APAC 15,876 — 15,876 15,516 — 15,516 Total revenues $ 31,385 $ 16,638 $ 48,023 $ 41,100 $ 8,708 $ 49,808
Contract with customer	The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): September 30, 2020 December 31, 2019 Contract Assets $ 975 $ 1,027 Unbilled receivables $ 14,985 $ 10,099 Contract Costs $ 130 $ — Contract Liabilities: Deferred Revenue $ 4,056 $ 2,044 During the three and nine months ended September 30, 2020 and 2019, we recognized the following revenues (in thousands): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 708 $ 5,092 $ 58 $ 4,948 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 233 2,641 854 2,460 Performance obligations satisfied from new activities in the period - contract revenue 17,444 14,173 47,111 42,400 Total revenues $ 18,385 $ 21,906 $ 48,023 $ 49,808
Performance obligation, expected timing of satisfaction	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2020. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands): Remainder of 2020 2021 2022 and Thereafter Total Product Revenue $ — $ 364 $ 1,623 $ 1,987 Research and development revenue 558 1,012 499 2,069 Total revenues $ 558 $ 1,376 $ 2,122 $ 4,056

Net income (loss) per Share (Ta

Net income (loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of earnings (loss) per share, basic and diluted	The following table sets forth the computation of basic and diluted net income (loss) per share during the three and nine months ended September 30, 2020 and 2019 (in thousands, except per share amounts): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Numerator: Net income (loss) (6,094) 343 (20,090) (11,300) Denominator: Weighted average common stock shares used in computing net income (loss) per share, basic 59,061 58,287 58,984 55,818 Effect of dilutive shares — 3,125 — — Weighted average common stock shares used in computing net income (loss) per share, diluted 59,061 61,412 58,984 55,818 Net income (loss) per share, basic $ (0.10) $ 0.01 $ (0.34) $ (0.20) Net income (loss) per share, diluted $ (0.10) $ 0.01 $ (0.34) $ (0.20)
Securities not included in the net loss per common share calculations	The following shares were not considered in the computation of diluted net income (loss) per share because their effect was anti-dilutive (in thousands): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Shares issuable under the Equity Incentive Plan 5,182 1,019 5,182 5,623

Cash Equivalents and Equity S_2

Cash Equivalents and Equity Securities (Tables)	9 Months Ended
	Sep. 30, 2020
Cash Equivalents and Marketable Securities [Abstract]
Schedule of cash equivalents	Cash equivalents at September 30, 2020 and December 31, 2019 consisted of the following (in thousands): September 30, 2020 December 31, 2019 Adjusted Cost Estimated Adjusted Cost Estimated Fair Value Money market funds (1) $ 51,488 $ 51,488 $ 71,248 $ 71,248 (1) Money market funds are classified in cash and cash equivalents on our unaudited condensed consolidated balance sheets.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Summary of financial instruments measured at fair value on a recurring basis	The following tables present the financial instruments that were measured at fair value on a recurring basis at September 30, 2020 and December 31, 2019 by level within the fair value hierarchy (in thousands): September 30, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 51,488 $ — $ — $ 51,488 December 31, 2019 Level 1 Level 2 Level 3 Total Money market funds $ 71,248 $ — $ — $ 71,248

Balance Sheets Details (Tables)

Balance Sheets Details (Tables)	9 Months Ended
	Sep. 30, 2020
Balance Sheets Details [Abstract]
Schedule of inventory components	Inventories consisted of the following (in thousands): September 30, 2020 December 31, 2019 Raw materials $ 77 $ 7 Work-in-process 28 26 Finished goods 632 338 Inventories $ 737 $ 371
Schedule of property and equipment, net	Property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Laboratory equipment $ 24,837 $ 23,561 Leasehold improvements 10,774 10,804 Computer equipment and software 3,134 3,016 Office equipment and furniture 1,175 1,461 Construction in progress 602 691 Property and equipment 40,522 39,533 Less: accumulated depreciation and amortization (33,233) (33,251) Property and equipment, net $ 7,289 $ 6,282
Schedule of other accrued liabilities	Other accrued liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrued purchases $ 3,810 $ 4,386 Accrued professional and outside service fees 3,142 1,802 Other 618 352 Total $ 7,570 $ 6,540

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense	Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Research and development $ 385 $ 458 $ 1,279 $ 1,249 Selling, general and administrative 1,599 1,274 4,813 4,534 Total $ 1,984 $ 1,732 $ 6,092 $ 5,783
Schedule of stock-based compensation expense by security types	The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 (in thousands): Three Months Ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Stock options $ 619 $ 545 $ 1,735 $ 1,680 RSUs and RSAs 603 461 1,812 1,308 PSUs 295 368 922 1,075 PBOs 467 358 1,623 1,720 Total $ 1,984 $ 1,732 $ 6,092 $ 5,783

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Lease cost	Lease related costs were as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Finance lease costs: Amortization of right-of-use assets $ 27 $ 54 $ 126 $ 163 Interest on lease obligations — 2 1 8 Finance lease costs 27 56 127 171 Operating lease cost 1,033 1,139 3,133 3,417 Short-term lease cost (1) — — 47 — Sublease income — (262) (55) (727) Total lease cost $ 1,060 $ 933 $ 3,252 $ 2,861 (1) Short-term lease costs on leases with terms of over one month and less than one year. Other information related to non-cancellable finance leases and operating leases as of September 30, 2020 was as follows: Operating Leases Weighted-average remaining lease term (in years) 6.9 years Weighted-average discount rate 6.6 % Cash paid for amounts included in the measurement of lease obligations was as follows (in thousands): Nine months ended September 30, 2020 2019 Operating cash flows from operating leases $ 1,795 $ 2,456 Operating cash flows from finance leases $ — $ 9 Financing cash flows from finance leases $ 60 $ 180
Operating lease maturity	As of September 30, 2020, our maturity analysis of annual undiscounted cash flows of the non-cancellable finance and operating leases are as follows (in thousands): Years ending December 31, Operating Leases 2020 (remaining 3 months) $ 1,022 2021 4,197 2022 4,285 2023 4,589 2024 4,726 2025 and thereafter 13,494 Total minimum lease payments 32,313 Less: imputed interest (6,758) Lease Obligations $ 25,555
Finance lease liability	As of September 30, 2020, our maturity analysis of annual undiscounted cash flows of the non-cancellable finance and operating leases are as follows (in thousands): Years ending December 31, Operating Leases 2020 (remaining 3 months) $ 1,022 2021 4,197 2022 4,285 2023 4,589 2024 4,726 2025 and thereafter 13,494 Total minimum lease payments 32,313 Less: imputed interest (6,758) Lease Obligations $ 25,555
Schedule of supply and service commitments	The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Other Commitment Agreement Type Agreement Date Future Minimum Payment Manufacture and supply agreement with expected future payment date of December 2022 April 2016 $ 532 Development and manufacturing services agreements September 2019 3,806 Strategic Collaboration and License Agreement March 2020 520 Total other commitments $ 4,858

Segment, Geographical and Oth_2

Segment, Geographical and Other Revenue Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of segment reporting	The following tables provide financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands): Three months ended September 30, 2020 Three months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 8,401 $ — $ 8,401 $ 10,351 $ — $ 10,351 Research and development revenue 4,604 5,380 9,984 10,073 1,482 11,555 Total revenues 13,005 5,380 18,385 20,424 1,482 21,906 Costs and operating expenses: Cost of product revenue 3,642 — 3,642 5,067 — 5,067 Research and development (1) 5,184 6,433 11,617 5,313 3,080 8,393 Selling, general and administrative (1) 2,675 515 3,190 2,037 690 2,727 Total segment costs and operating expenses 11,501 6,948 18,449 12,417 3,770 16,187 Income (loss) from operations $ 1,504 $ (1,568) (64) $ 8,007 $ (2,288) 5,719 Corporate costs (2) (5,483) (4,912) Depreciation and amortization (528) (471) Income (loss) before income taxes $ (6,075) $ 336 (1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses. Nine months ended September 30, 2020 Nine months ended September 30, 2019 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 18,005 $ — $ 18,005 $ 24,588 $ — $ 24,588 Research and development revenue 13,380 16,638 30,018 16,512 8,708 25,220 Total revenues 31,385 16,638 48,023 41,100 8,708 49,808 Costs and operating expenses: Cost of product revenue 7,882 — 7,882 12,230 — 12,230 Research and development (1) 15,877 16,848 32,725 14,889 9,252 24,141 Selling, general and administrative (1) 7,395 1,728 9,123 6,499 1,768 8,267 Total segment costs and operating expenses 31,154 18,576 49,730 33,618 11,020 44,638 Income (loss) from operations $ 231 $ (1,938) (1,707) $ 7,482 $ (2,312) 5,170 Corporate costs (2) (16,526) (15,185) Depreciation and amortization (1,526) (1,273) Loss before income taxes $ (19,759) $ (11,288) (1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses. The following tables provides stock-based compensation expense included in income (loss) from operations (in thousands): Three months ended September 30, 2020 2019 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 839 $ 132 $ 1,013 $ 1,984 $ 736 $ 225 $ 771 $ 1,732 Nine months ended September 30, 2020 2019 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 2,335 $ 625 $ 3,132 $ 6,092 $ 1,973 $ 563 $ 3,247 $ 5,783
Schedule of customers that contributed 10% or more of total accounts receivable	Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Customer A 23% 21% 21% 31% Customer B 15% * 13% 17% Customer C * 29% 11% 15% Customer D 14% * 22% * Customer E 13% * * * Customers that each accounted for 10% or more of accounts receivable had balances as of the periods presented as follows: Percentage of Accounts Receivables as of September 30, 2020 December 31, 2019 Customer A 36% 38% Customer B 28% 10% Customer D 14% * * Percentage was less than 10%
Schedule of revenues by geographical area	Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Revenues Americas $ 5,841 $ 2,706 $ 17,972 $ 9,620 EMEA 4,889 12,205 14,175 24,672 APAC 7,655 6,995 15,876 15,516 Total revenues $ 18,385 $ 21,906 $ 48,023 $ 49,808
Schedule of long-lived assets by geographical area	Identifiable long-lived assets by location was as follows (in thousands): Long-lived assets September 30, 2020 December 31, 2019 United States $ 7,289 $ 6,282
Schedule of intangible assets and goodwill	Identifiable goodwill was as follows (in thousands): As of September 30, 2020 and December 31, 2019 Performance Enzymes Novel Biotherapeutics Total Goodwill $ 2,463 $ 778 $ 3,241

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Analysis of allowance for credit losses	An analysis of the allowance for credit losses is as follows (in thousands): Three and nine Beginning Balance January 1, 2020 $ 34 Current period provision 40 Write-offs charged against the allowance — Recoveries of amounts previously written off — Ending Balance September 30, 2020 $ 74
Summary of accounts receivable by aging	The following tables below summarizes accounts receivable by aging category (in thousands): September 30, 2020 31-60 Days 61-90 Days 91 days and over Total over 31 days Current Total balance Accounts receivable $ 160 $ — $ — $ 160 $ 10,551 $ 10,711 December 31, 2019 31-60 Days 61-90 Days 91 days and over Total over 31 days Current Total balance Accounts receivable $ 185 $ 7 $ 65 $ 257 $ 8,806 $ 9,063

Description of Business (Detail

Description of Business (Details) $ in Millions	1 Months Ended
	Mar. 31, 2020USD ($)program	Dec. 31, 2018USD ($)
Nestec Ltd. (Nestle Health Sciences) [Member] | CDX-6114 [Member] | Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment amount | $		$ 1
Duration to pay after milestone achievement (in days)		60 days
Takeda [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of initial programs | program	3
Number of additional programs | program	4
One-time, non-refundable cash payment | $	$ 8.5

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details) $ in Thousands	Jan. 01, 2018USD ($)reportingUnit	Sep. 30, 2020USD ($)reportingUnit	Sep. 30, 2020USD ($)segment	Dec. 31, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reporting units | reportingUnit	2	2
Goodwill		$ 3,241	$ 3,241	$ 3,241
Number of reportable segments		2	2
Performance Enzymes [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Goodwill, allocated percent	76.00%
Goodwill	$ 2,400
Novel Biotherapeutics [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Goodwill, allocated percent	24.00%
Goodwill	$ 800

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 18,385	$ 21,906	$ 48,023	$ 49,808
Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	5,841	2,706	17,972	9,620
EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,889	12,205	14,175	24,672
APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,655	6,995	15,876	15,516
Product Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	8,401	10,351	18,005	24,588
Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	9,984	11,555	30,018	25,220
Performance Enzymes [Member]
Disaggregation of Revenue [Line Items]
Total revenues	13,005	20,424	31,385	41,100
Performance Enzymes [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,209	2,706	7,381	9,620
Performance Enzymes [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	2,141	10,723	8,128	15,964
Performance Enzymes [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,655	6,995	15,876	15,516
Performance Enzymes [Member] | Product Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	8,401	10,351	18,005	24,588
Performance Enzymes [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,604	10,073	13,380	16,512
Novel Biotherapeutics [Member]
Disaggregation of Revenue [Line Items]
Total revenues	5,380	1,482	16,638	8,708
Novel Biotherapeutics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	2,632	0	10,591	0
Novel Biotherapeutics [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	2,748	1,482	6,047	8,708
Novel Biotherapeutics [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Product Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 5,380	$ 1,482	$ 16,638	$ 8,708

Revenue Recognition - Contracts

Revenue Recognition - Contracts with Customer (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Contract assets	$ 975	$ 1,027
Unbilled receivables	14,985	10,099
Contract Costs	130	0
Contract Liabilities: Deferred Revenue	$ 4,056	$ 2,044

Revenue Recognition - Textual (

Revenue Recognition - Textual (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Impairment charges related to contract assets	$ 0	$ 0	$ 0	$ 0

Revenue Recognition - Revenue R

Revenue Recognition - Revenue Recognized During Period (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Performance obligations satisfied	$ 708	$ 5,092	$ 58	$ 4,948
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	233	2,641	854	2,460
Performance obligations satisfied from new activities in the period - contract revenue	17,444	14,173	47,111	42,400
Total revenues	$ 18,385	$ 21,906	$ 48,023	$ 49,808

Revenue Recognition - Performan

Revenue Recognition - Performance Obligation (Details) $ in Thousands	Sep. 30, 2020USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 4,056
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 558
Expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,376
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 2,122
Expected timing of satisfaction, period
Product Revenue [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,987
Product Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 0
Expected timing of satisfaction, period	3 months
Product Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 364
Expected timing of satisfaction, period	1 year
Product Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,623
Expected timing of satisfaction, period
Research and Development Revenue [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 2,069
Research and Development Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 558
Expected timing of satisfaction, period	3 months
Research and Development Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,012
Expected timing of satisfaction, period	1 year
Research and Development Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 499
Expected timing of satisfaction, period

Net income (loss) per Share - E

Net income (loss) per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net income	$ (6,094)	$ 343	$ (20,090)	$ (11,300)
Denominator:
Weighted average common stock shares used in computing net income (loss) per share, basic (shares)	59,061	58,287	58,984	55,818
Effect of dilutive shares (shares)	0	3,125	0	0
Weighted average common stock shares used in computing net income (loss) per share, diluted (shares)	59,061	61,412	58,984	55,818
Net income (loss) per share, basic (usd per share)	$ (0.10)	$ 0.01	$ (0.34)	$ (0.20)
Net income (loss) per share, diluted (usd per share)	$ (0.10)	$ 0.01	$ (0.34)	$ (0.20)

Net income (loss) per Share - A

Net income (loss) per Share - Anti-Dilutive Securities (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Shares Issuable Under the Equity Incentive Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded as anti-dilutive (shares)	5,182	1,019	5,182	5,623

Collaborative Arrangements - GS

Collaborative Arrangements - GSK Platform Technology Transfer, Collaboration and License Agreement (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jul. 31, 2014
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized	$ 18,385,000	$ 21,906,000	$ 48,023,000	$ 49,808,000
GSK [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized					$ 2,000,000
GSK [Member] | Research and Development Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized	$ 0	$ 2,000,000	$ 0	$ 2,000,000
GSK [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable						$ 5,750,000
GSK [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable						$ 38,500,000

Collaborative Arrangements - Me

Collaborative Arrangements - Merck Platform Technology Transfer and License Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Aug. 31, 2015
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized	$ 18,385	$ 21,906	$ 48,023	$ 49,808
Contract with customer, liability	4,056		4,056		$ 2,044
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable						$ 15,000
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member] | Research and Development Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized	$ 1,100	1,100	$ 2,100	4,000
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member] | License Fee [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		$ 100		$ 1,000

Collaborative Arrangements - _2

Collaborative Arrangements - Merck Sitagliptin Catalyst Supply Agreement (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Dec. 31, 2015	Feb. 29, 2012	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized			$ 18,385	$ 21,906	$ 48,023	$ 49,808
Merck [Member] | Supply Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term of collaborative research and development agreement		5 years
Optional extension period	5 years
Merck [Member] | Supply Agreement [Member] | Product Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized			$ 3,200	$ 3,600	$ 7,000	$ 11,400

Collaborative Arrangements - En

Collaborative Arrangements - Enzyme Supply Agreement (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	$ 4,056	$ 2,044
Supply Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	$ 2,000	$ 2,000

Collaborative Arrangements - Gl

Collaborative Arrangements - Global Development, Option and License Agreement, Strategic Collaboration Agreement, and Development Agreement (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 30, 2018	Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability		$ 4,056,000		$ 4,056,000		$ 2,044,000
Revenue recognized		18,385,000	$ 21,906,000	48,023,000	$ 49,808,000
Nestec Ltd. (Nestle Health Sciences) [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		2,800,000	1,400,000	6,100,000	3,900,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Strategic Collaboration Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability							$ 600,000	$ 1,200,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	$ 14,000,000
Revenue recognized		$ 0	$ 100,000	$ 0	$ 1,800,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Sales-Based Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Target sales for milestone	1,000,000,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Maximum [Member] | Research and Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable	85,000,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Maximum [Member] | Sales-Based Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable	250,000,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Milestone One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	4,000,000
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Milestone Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	$ 1,000,000
Nestec Ltd. (Nestle Health Sciences) [Member] | CDX-6114 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cumulative catch-up adjustment to revenue, change in measure of progress						$ 3,000,000

Collaborative Arrangements - St

Collaborative Arrangements - Strategic Collaboration Agreement (Details) - USD ($)	1 Months Ended		3 Months Ended			9 Months Ended
	Apr. 30, 2020	Apr. 30, 2018	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability			$ 4,056,000			$ 4,056,000		$ 2,044,000
Revenue recognized			18,385,000	$ 21,906,000		48,023,000	$ 49,808,000
Porton [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability			100,000			100,000		$ 0
Revenue recognized	$ 1,000,000		$ 0	$ 0	$ 2,800,000	$ 1,100,000	$ 0
Porton [Member] | Milestone One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability		$ 500,000
Number of days for payment		30 days
Porton [Member] | Milestone Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable		$ 1,500,000
Porton [Member] | Milestone Three [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable		$ 1,000,000

Collaborative Arrangements - Pl

Collaborative Arrangements - Platform Technology Transfer and License Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability		$ 4,056		$ 4,056			$ 2,044
Revenue recognized		18,385	$ 21,906	48,023	$ 49,808
Novartis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term of collaborative research and development agreement	23 months
Contract with customer, liability	$ 5,000
Revenue recognized		$ 900	$ 3,800	$ 4,100	$ 3,800
Novartis [Member] | Royalty [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term of collaborative research and development agreement	23 months
Novartis [Member] | Computer Equipment and Software [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent annual receivable increase	$ 8,000
Novartis [Member] | Milestone One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable						$ 4,000
Novartis [Member] | Milestone Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable	$ 5,000

Collaborative Arrangements - Li

Collaborative Arrangements - License Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		$ 18,385	$ 21,906	$ 48,023	$ 49,808
Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		$ 100		$ 900
Roche [Member] | Milestone One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of days for payment	45 days
Roche [Member] | Milestone Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of days for payment	60 days

Collaborative Arrangements - _3

Collaborative Arrangements - Strategic Collaboration and License Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Mar. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	$ 4,056		$ 4,056			$ 2,044
Revenue recognized	18,385	$ 21,906	48,023	$ 49,808
Takeda [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	1,900		1,900
Revenue recognized	$ 2,600		$ 10,600
Takeda [Member] | Up-front Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability					$ 8,500
Takeda [Member] | Research and Development Reimbursement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable					18,300
Takeda [Member] | Milestone Payment Per Target Gene [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable					$ 100,000

Collaborative Arrangements - Ma

Collaborative Arrangements - Master Collaboration and Research Agreement and Stock Purchase Agreement (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire other investments			$ 1,000,000	$ 0
Contract with customer, liability		$ 4,056,000	$ 4,056,000		$ 2,044,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected timing of satisfaction, period		3 months	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected timing of satisfaction, period		1 year	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected timing of satisfaction, period
Research and Development Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected timing of satisfaction, period		3 months	3 months
Research and Development Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected timing of satisfaction, period		1 year	1 year
Research and Development Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected timing of satisfaction, period
Molecular Assemblies, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Due from affiliate		$ 500,000	$ 500,000
Molecular Assemblies, Inc. [Member] | MCRA [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development revenue from transactions with MAI		$ 500,000	$ 500,000
Molecular Assemblies, Inc. [Member] | MCRA [Member] | Fixed Consideration [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of days for payment	30 days
Molecular Assemblies, Inc. [Member] | MCRA [Member] | Bonus Goal Met [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of days for payment	30 days
Molecular Assemblies, Inc. [Member] | CESA [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate commercial sales, milestone	$ 5,000,000
Molecular Assemblies, Inc. [Member] | CESA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-06-22
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected timing of satisfaction, period	6 months
Molecular Assemblies, Inc. [Member] | CESA [Member] | Royalty [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	$ 500,000
Molecular Assemblies, Inc. [Member] | Series A Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares purchased	1,587,050
Payments to acquire other investments	$ 1,000,000

Collaborative Arrangements - Pe

Collaborative Arrangements - Performance Period (Details)	Sep. 30, 2020	Jun. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period
Molecular Assemblies, Inc. [Member] | CESA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-06-22
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		6 months
Molecular Assemblies, Inc. [Member] | Minimum [Member] | MCRA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-02-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		10 months
Molecular Assemblies, Inc. [Member] | Maximum [Member] | MCRA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		13 months
Molecular Assemblies, Inc. [Member] | Maximum [Member] | MCRA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-08-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		13 months

Cash Equivalents and Equity S_3

Cash Equivalents and Equity Securities - Components of Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Cash Equivalents and Marketable Securities [Line Items]
Cash and cash equivalents	$ 71,516	$ 90,498	$ 92,143
Money Market Funds [Member]
Cash Equivalents and Marketable Securities [Line Items]
Cash and cash equivalents	51,488	71,248
Cash and cash equivalents, fair value	$ 51,488	$ 71,248

Cash Equivalents and Equity S_4

Cash Equivalents and Equity Securities - Textual (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 71,516	$ 90,498	$ 92,143
Investment at cost basis	$ 1,000	0
Molecular Assemblies, Inc. [Member]
Cash and Cash Equivalents [Line Items]
Ownership percentage	4.00%
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 51,488	71,248
Cash [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 20,000	$ 19,300

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Money Market Funds [Member] - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	$ 51,488	$ 71,248
Level 1 [Member]
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	$ 51,488	$ 71,248

Balance Sheets Details - Invent

Balance Sheets Details - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule of Inventory Components
Raw materials	$ 77	$ 7
Work-in-process	28	26
Finished goods	632	338
Inventories	$ 737	$ 371

Balance Sheets Details - Proper

Balance Sheets Details - Property and Equipment, net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment	$ 40,522	$ 39,533
Less: accumulated depreciation and amortization	(33,233)	(33,251)
Property and equipment, net	7,289	6,282
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	24,837	23,561
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	10,774	10,804
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	3,134	3,016
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,175	1,461
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 602	$ 691

Balance Sheets Details - Goodwi

Balance Sheets Details - Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Balance Sheet Details [Abstract]
Goodwill	$ 3,241	$ 3,241

Balance Sheets Details - Other

Balance Sheets Details - Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Balance Sheets Details [Abstract]
Accrued purchases	$ 3,810	$ 4,386
Accrued professional and outside service fees	3,142	1,802
Other	618	352
Total	$ 7,570	$ 6,540

Stock-based Compensation - Equi

Stock-based Compensation - Equity Incentive Plans (Details) - 2019 Plan [Member]	Jun. 30, 2019shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant	7,897,144
Maximum number of shares to be issued upon exercise of stock options	14,000,000
Number of shares authorized	8,100,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Options (Details)	9 Months Ended
	Sep. 30, 2020
Incentive Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	100.00%
Non-Statutory Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	85.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of voting interests	10.00%
Purchase price of common stock above minimum threshold	110.00%
Expiration period	10 years
Award vesting period	4 years
Stock Options [Member] | Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)	25.00%
Stock Options [Member] | Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)	75.00%

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units (Details) - RSUs [Member]	9 Months Ended
	Sep. 30, 2020
Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Award vesting rights (percent)	33.00%
Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Award vesting rights (percent)	25.00%

Stock-based Compensation - PSUs

Stock-based Compensation - PSUs and PBOs (Details) - Performance Shares [Member] - installment	3 Months Ended			9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance awards, threshold level, number of shares, multiplier				0
2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments				2
2019 Plan [Member] | Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)				50.00%
2019 Plan [Member] | Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)				50.00%
2020 PSU and PBO Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate				100.00%
2019 PSU and PBO Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate		106.00%
2019 PSU and PBO Plan [Member] | Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)		50.00%
2019 PSU and PBO Plan [Member] | Tranche Two [Member] | Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)	50.00%
2018 PSU and PBO Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate			118.00%
2018 PSU and PBO Plan [Member] | Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)			50.00%
2018 PSU and PBO Plan [Member] | Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)		50.00%

Stock-based Compensation - St_2

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Aug. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Schedule of stock-based compensation expense
Stock-based compensation			$ 1,984	$ 1,732	$ 6,092	$ 5,783
Nonemployee [Member]
Schedule of stock-based compensation expense
Number of options granted (shares)	16,000	60,000
Fair value of options granted	$ 100	$ 300
Stock Options [Member]
Schedule of stock-based compensation expense
Stock-based compensation			619	545	$ 1,735	1,680
Award vesting period					4 years
Compensation not yet recognized, stock options			4,200		$ 4,200
Stock Options [Member] | Tranche One [Member]
Schedule of stock-based compensation expense
Award vesting rights (percent)					25.00%
Stock Options [Member] | Tranche Two [Member]
Schedule of stock-based compensation expense
Award vesting rights (percent)					75.00%
RSUs and RSAs [Member]
Schedule of stock-based compensation expense
Stock-based compensation			603	461	$ 1,812	1,308
Compensation not yet recognized, share-based awards other than options			2,300		2,300
PSUs [Member]
Schedule of stock-based compensation expense
Stock-based compensation			295	368	922	1,075
Compensation not yet recognized, share-based awards other than options			800		800
PBOs [Member]
Schedule of stock-based compensation expense
Stock-based compensation			467	358	1,623	1,720
Compensation not yet recognized, share-based awards other than options			1,300		1,300
Non-Employee Stock Options [Member]
Schedule of stock-based compensation expense
Compensation not yet recognized, stock options			300		300
Non-Employee Stock Options [Member] | Nonemployee [Member]
Schedule of stock-based compensation expense
Expected volatility rate	50.50%	51.90%
Risk free interest rate	0.30%	0.40%
Expected dividend yield	0.00%	0.00%
Award vesting period	1 year	2 years
Stock-based compensation expense			43		47
Non-Employee Stock Options [Member] | Nonemployee [Member] | Tranche One [Member]
Schedule of stock-based compensation expense
Award vesting rights (percent)		50.00%
Non-Employee Stock Options [Member] | Nonemployee [Member] | Tranche Two [Member]
Schedule of stock-based compensation expense
Award vesting rights (percent)	100.00%	50.00%
Research and Development [Member]
Schedule of stock-based compensation expense
Stock-based compensation			385	458	1,279	1,249
Selling, General and Administrative [Member]
Schedule of stock-based compensation expense
Stock-based compensation			$ 1,599	$ 1,274	$ 4,813	$ 4,534

Capital Stock - Exercise of Opt

Capital Stock - Exercise of Options (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Equity [Abstract]
Stock options exercised (shares)	87,240	970,256
Weighted average exercise price of stock options exercised (usd per share)	$ 6.17	$ 4.76
Proceeds from exercises of stock options	$ 539	$ 4,621

Capital Stock - Private Offerin

Capital Stock - Private Offering (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Subsidiary, Sale of Stock [Line Items]
Issuance costs		$ 0	$ 129
Private Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold	3,048,780
Purchase price (usd per share)	$ 16.40
Issuance costs	$ 74
Net proceeds received	$ 49,900

Commitments and Contingencies -

Commitments and Contingencies - Textual (Details)	Jun. 30, 2017USD ($)	Apr. 30, 2017USD ($)	Feb. 28, 2017USD ($)	Sep. 30, 2020USD ($)ft²securitynumberOfRenewalOption	Dec. 31, 2019USD ($)	Apr. 30, 2020ft²	Jan. 31, 2020ft²
Commitments and Contingencies [Line Items]
Area of real estate property (square feet) | ft²				77,300
Number of buildings leased | security				4
Number of options to extend | numberOfRenewalOption				2
Renewal term				5 years
Asset retirement obligations				$ 200,000	$ 200,000
Accretion expense related to asset retirement obligation				0	0
Capital lease obligations incurred		$ 300,000	$ 400,000
Term of contract		3 years	3 years
Credit Availability Concentration Risk [Member]
Commitments and Contingencies [Line Items]
Concentration risk, percentage	80.00%
Indemnification Agreement [Member]
Commitments and Contingencies [Line Items]
Loss contingency accrual				$ 0
Term Loan [Member]
Commitments and Contingencies [Line Items]
Borrowing capacity	$ 10,000,000
Basis spread on variable rate (percent)				0.50%
Stated interest rate				3.75%
Revolving Credit Facility [Member]
Commitments and Contingencies [Line Items]
Borrowing capacity	$ 5,000,000
Basis spread on variable rate (percent)				1.00%
Stated interest rate				4.25%
Demand Deposits [Member]
Commitments and Contingencies [Line Items]
Non-current restricted cash				$ 1,100,000	$ 1,100,000
200-220 Penobscot [Member]
Commitments and Contingencies [Line Items]
Area of real estate property (square feet) | ft²				28,200
400 Penobscot [Member]
Commitments and Contingencies [Line Items]
Area of real estate property (square feet) | ft²				37,900
501 Chesapeake [Member]
Commitments and Contingencies [Line Items]
Area of real estate property (square feet) | ft²				11,200
101 Saginaw [Member]
Commitments and Contingencies [Line Items]
Area of real estate property (square feet) | ft²							29,900
Sublease [Member]
Commitments and Contingencies [Line Items]
Area of real estate property (square feet) | ft²						3,400	26,500

Commitments and Contingencies_2

Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Finance lease costs:
Amortization of right-of-use assets	$ 27	$ 54	$ 126	$ 163
Interest on lease obligations	0	2	1	8
Finance lease costs	27	56	127	171
Operating lease cost	1,033	1,139	3,133	3,417
Short-term lease cost	0	0	47	0
Sublease income	0	(262)	(55)	(727)
Total lease cost	$ 1,060	$ 933	$ 3,252	$ 2,861

Commitments and Contingencies_3

Commitments and Contingencies - Other Lease Information (Details)	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term (in years)	6 years 10 months 24 days
Weighted-average discount rate	6.60%

Commitments and Contingencies_4

Commitments and Contingencies - Cash Paid for Lease Obligations (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows from operating leases	$ 1,795	$ 2,456
Operating cash flows from finance leases	0	9
Finance Lease, Principal Payments	$ 60	$ 180

Commitments and Contingencies_5

Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2020USD ($)
Operating Leases
2020 (remaining 3 months)	$ 1,022
2021	4,197
2022	4,285
2023	4,589
2024	4,726
2025 and thereafter	13,494
Total minimum lease payments	32,313
Less: imputed interest	(6,758)
Lease Obligations	$ 25,555

Commitments and Contingencies_6

Commitments and Contingencies - Other Commitments (Details) - Supply Commitment [Member] $ in Thousands	Sep. 30, 2020USD ($)
Other Commitments [Line Items]
Future Minimum Payment	$ 4,858
April 2016 [Member]
Other Commitments [Line Items]
Future Minimum Payment	532
September 2019 [Member]
Other Commitments [Line Items]
Future Minimum Payment	3,806
March 2020 [Member]
Other Commitments [Line Items]
Future Minimum Payment	$ 520

Related Party - Molecular Assem

Related Party - Molecular Assemblies, Inc. (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Contract with customer, liability		$ 4,056,000	$ 4,056,000	$ 2,044,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Related Party Transaction [Line Items]
Expected timing of satisfaction, period		3 months	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Related Party Transaction [Line Items]
Expected timing of satisfaction, period		1 year	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Related Party Transaction [Line Items]
Expected timing of satisfaction, period
Molecular Assemblies, Inc. [Member]
Related Party Transaction [Line Items]
Due from affiliate		$ 500,000	$ 500,000
Molecular Assemblies, Inc. [Member] | MCRA [Member]
Related Party Transaction [Line Items]
Research and development revenue from transactions with MAI		$ 500,000	$ 500,000
Molecular Assemblies, Inc. [Member] | MCRA [Member] | Maximum [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Related Party Transaction [Line Items]
Expected timing of satisfaction, period	13 months
Molecular Assemblies, Inc. [Member] | MCRA [Member] | Maximum [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-08-01
Related Party Transaction [Line Items]
Expected timing of satisfaction, period	13 months
Molecular Assemblies, Inc. [Member] | MCRA [Member] | Minimum [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-02-01
Related Party Transaction [Line Items]
Expected timing of satisfaction, period	10 months
Molecular Assemblies, Inc. [Member] | CESA [Member]
Related Party Transaction [Line Items]
Aggregate commercial sales, milestone	$ 5,000,000
Molecular Assemblies, Inc. [Member] | CESA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-06-22
Related Party Transaction [Line Items]
Expected timing of satisfaction, period	6 months
Molecular Assemblies, Inc. [Member] | CESA [Member] | Royalty [Member]
Related Party Transaction [Line Items]
Contract with customer, liability	$ 500,000

Related Party - Performance Per

Related Party - Performance Period (Details)	Sep. 30, 2020	Jun. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period
Molecular Assemblies, Inc. [Member] | CESA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-06-22
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		6 months
Molecular Assemblies, Inc. [Member] | Minimum [Member] | MCRA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-02-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		10 months
Molecular Assemblies, Inc. [Member] | Maximum [Member] | MCRA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		13 months
Molecular Assemblies, Inc. [Member] | Maximum [Member] | MCRA [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-08-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction, period		13 months

Related Party - AstraZeneca PLC

Related Party - AstraZeneca PLC (Details) - Director [Member] - Transactions With AstraZeneca PLC [Member] - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Revenue from related parties	$ 200,000	$ 100,000	$ 600,000
Accounts receivable from related parties		$ 0		$ 0

Segment, Geographical and Oth_3

Segment, Geographical and Other Revenue Information - Textual (Details) - 9 months ended Sep. 30, 2020	reportingUnit	segment
Segment Reporting [Abstract]
Number of operating segments		2
Number of reportable segments	2	2

Segment, Geographical and Oth_4

Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Total revenues	$ 18,385	$ 21,906	$ 48,023	$ 49,808
Cost of product revenue	3,642	5,067	7,882	12,230
Research and development	12,010	8,711	33,830	25,000
Selling, general and administrative	8,797	7,869	26,307	24,180
Total costs and operating expenses	24,449	21,647	68,019	61,410
Income (loss) from operations	(6,064)	259	(19,996)	(11,602)
Depreciation and amortization			(1,403)	(1,118)
Income (loss) before income taxes	(6,075)	336	(19,759)	(11,288)
Stock-based compensation	1,984	1,732	6,092	5,783
Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	13,005	20,424	31,385	41,100
Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	5,380	1,482	16,638	8,708
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	18,385	21,906	48,023	49,808
Cost of product revenue	3,642	5,067	7,882	12,230
Research and development	11,617	8,393	32,725	24,141
Selling, general and administrative	3,190	2,727	9,123	8,267
Total costs and operating expenses	18,449	16,187	49,730	44,638
Income (loss) from operations	(64)	5,719	(1,707)	5,170
Stock-based compensation	1,984	1,732	6,092	5,783
Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	13,005	20,424	31,385	41,100
Cost of product revenue	3,642	5,067	7,882	12,230
Research and development	5,184	5,313	15,877	14,889
Selling, general and administrative	2,675	2,037	7,395	6,499
Total costs and operating expenses	11,501	12,417	31,154	33,618
Income (loss) from operations	1,504	8,007	231	7,482
Stock-based compensation	839	736	2,335	1,973
Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	5,380	1,482	16,638	8,708
Cost of product revenue	0	0	0	0
Research and development	6,433	3,080	16,848	9,252
Selling, general and administrative	515	690	1,728	1,768
Total costs and operating expenses	6,948	3,770	18,576	11,020
Income (loss) from operations	(1,568)	(2,288)	(1,938)	(2,312)
Stock-based compensation	132	225	625	563
Corporate [Member]
Segment Reporting Information [Line Items]
Total costs and operating expenses	(5,483)	(4,912)	(16,526)	(15,185)
Depreciation and amortization	(528)	(471)	(1,526)	(1,273)
Income (loss) before income taxes	(6,075)	336	(19,759)	(11,288)
Stock-based compensation	1,013	771	3,132	3,247
Product Revenue [Member]
Segment Reporting Information [Line Items]
Total revenues	8,401	10,351	18,005	24,588
Product Revenue [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	8,401	10,351	18,005	24,588
Product Revenue [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Product Revenue [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	8,401	10,351	18,005	24,588
Product Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	8,401	10,351	18,005	24,588
Research and Development Revenue [Member]
Segment Reporting Information [Line Items]
Total revenues	9,984	11,555	30,018	25,220
Research and Development Revenue [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	4,604	10,073	13,380	16,512
Research and Development Revenue [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	5,380	1,482	16,638	8,708
Research and Development Revenue [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	9,984	11,555	30,018	25,220
Research and Development Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	4,604	10,073	13,380	16,512
Research and Development Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	$ 5,380	$ 1,482	$ 16,638	$ 8,708

Segment, Geographical and Oth_5

Segment, Geographical and Other Revenue Information - Concentration Risk (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue, Product and Service Benchmark [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	23.00%	21.00%	21.00%	31.00%
Revenue, Product and Service Benchmark [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%		13.00%	17.00%
Revenue, Product and Service Benchmark [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		29.00%	11.00%	15.00%
Revenue, Product and Service Benchmark [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%		22.00%
Revenue, Product and Service Benchmark [Member] | Customer E [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			36.00%		38.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			28.00%		10.00%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			14.00%

Segment, Geographical and Oth_6

Segment, Geographical and Other Revenue Information - Revenues by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Total revenues	$ 18,385	$ 21,906	$ 48,023	$ 49,808
Americas [Member]
Segment Reporting Information [Line Items]
Total revenues	5,841	2,706	17,972	9,620
EMEA [Member]
Segment Reporting Information [Line Items]
Total revenues	4,889	12,205	14,175	24,672
APAC [Member]
Segment Reporting Information [Line Items]
Total revenues	$ 7,655	$ 6,995	$ 15,876	$ 15,516

Segment, Geographical and Oth_7

Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule of long-lived assets by geographical area
Long-lived assets	$ 7,289	$ 6,282
United States [Member]
Schedule of long-lived assets by geographical area
Long-lived assets	$ 7,289	$ 6,282

Segment, Geographical and Oth_8

Segment, Geographical and Other Revenue Information - Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Jan. 01, 2018
Segment Reporting Information [Line Items]
Goodwill	$ 3,241	$ 3,241
Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Goodwill			$ 2,400
Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Goodwill			$ 800
Operating Segments [Member]
Segment Reporting Information [Line Items]
Goodwill	3,241	3,241
Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Goodwill	2,463	2,463
Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Goodwill	$ 778	$ 778

Allowance for Credit Losses - A

Allowance for Credit Losses - Analysis of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Beginning Balance January 1, 2020	$ 34
Current period provision	40	$ 0
Write-offs charged against the allowance	0
Recoveries of amounts previously written off	0
Ending Balance September 30, 2020	$ 74

Allowance for Credit Losses - S

Allowance for Credit Losses - Summary of Finance Receivables by Aging Category (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Financing Receivable, Allowance for Credit Loss [Line Items]
Past due	$ 160	$ 257
Current	10,551	8,806
Total balance	10,711	9,063
31-60 Days [Member]
Financing Receivable, Allowance for Credit Loss [Line Items]
Past due	160	185
61-90 Days [Member]
Financing Receivable, Allowance for Credit Loss [Line Items]
Past due	0	7
91 Days and Over [Member]
Financing Receivable, Allowance for Credit Loss [Line Items]
Past due	$ 0	$ 65

Uncategorized Items - cdxs-2020

Label	Element	Value
Restricted Cash and Cash Equivalents	us-gaap_RestrictedCashAndCashEquivalents	$ 1,695,000
Restricted Cash and Cash Equivalents	us-gaap_RestrictedCashAndCashEquivalents	$ 1,731,000